

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/018440 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 265/30**,  
A61K 31/5375, A61P 25/24

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

(21) International Application Number:  
PCT/US2003/023268

(22) International Filing Date: 18 August 2003 (18.08.2003)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0219685.5 23 August 2002 (23.08.2002) GB  
60/415,327 1 October 2002 (01.10.2002) US

#### Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for the following desig-  
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,  
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,  
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,  
ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,  
PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (for all designated States except US): ELI  
LILLY AND COMPANY [US/US]; Lilly Corporate  
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLARK, Barry,  
Peter [GB/GB]; ELI LILLY AND COMPANY LIMITED,  
Kingsclere Road, Basingstoke, Hampshire RG21 2XA  
(GB). GALLAGHER, Peter, Thaddeus [GB/GB]; ELI  
LILLY AND COMPANY LIMITED, Kingsclere Road,  
Basingstoke, Hampshire RG21 2XA (GB). HAUGHTON,  
Helen, Louise [GB/GB]; ELI LILLY AND COMPANY  
LIMITED, Kingsclere Road, Basingstoke, Hampshire  
RG21 2XA (GB).

(74) Agents: SALES, James, J. et al.; ELI LILLY AND COM-  
PANY, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).


#### Published:

- with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(81) Designated States (*national*): AE, AG, AL, AM, AT (uti-  
lity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (uti-  
lity model), DE, DK (utility model), DK, DM, DZ, EC, EE  
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BENZYL MORPHOLINE DERIVATIVES



(I)

(57) Abstract: A compound of formula (I) (I) wherein R is H; Ar is  
an aromatic group selected from phenyl; X is a phenyl group; R' is  
H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and  
pharmaceutically acceptable salts thereof.

WO 2004/018440 A1

## BENZYL MORPHOLINE DERIVATIVES

This invention relates to novel benzyl morpholine compounds, and to their use in inhibiting serotonin and norepinephrine reuptake.

5 Serotonin has been implicated in the aetiology of many disease states and has been found to be of importance in mental illnesses, depression, anxiety, schizophrenia, eating disorders, obsessive compulsive disorder (OCD) and migraine. Indeed many currently used treatments of these disorders are thought to act by modulating serotonergic tone. During the last decade, multiple serotonin receptor subtypes have been  
10 characterised. This has led to the realisation that many treatments act *via* the serotonergic system, such as selective serotonin reuptake inhibitor (SSRI) antidepressants which increase serotonin transmission, for example, the hydrochloride salt of fluoxetine.

Drugs that exert their main action on the norepinephrinergic system have been available for some time, however their lack of selectivity has made it difficult to  
15 determine specific clinical effects produced by a selective action on norepinephrine reuptake. Accumulating evidence indicates that the norepinephrinergic system modulates drive and energy, whereas the serotonergic system modulates mood. Thus norepinephrine appears to play an important role in the disturbances of vegetative function associated with affective, anxiety and cognitive disorders. Atomoxetine hydrochloride is a selective  
20 inhibitor of norepinephrine reuptake, and is marketed for the treatment of attention deficit hyperactivity disorder (ADHD). Reboxetine is also a selective norepinephrine reuptake inhibitor and is marketed for the treatment of depression. WO99/15177 discloses the use of Reboxetine to treat ADHD and WO01/01973 discloses the use of S,S-Reboxetine to treat ADHD.

25 Norepinephrine and serotonin receptors are known to interact anatomically and pharmacologically. Compounds that affect only serotonin have been shown to exhibit modulatory effects on norepinephrine, pointing toward an important relationship between the two neurotransmitter systems.


Duloxetine, (+)-*N*-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine  
30 hydrochloride, inhibits the reuptake of both norepinephrine and serotonin, and is currently under development for the treatment of depression and urinary incontinence. The compound duloxetine was disclosed in US Patents 5,023,269 and 4,956,388.

BEST AVAILABLE COPY

-51-

benzylmorpholin-3-one and (2S)-2-[(R)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one (2.42g 7.68mmol) in dried tetrahydrofuran (30ml) at room temperature under nitrogen causing effervescence. The solution was heated to 60°C for 2h, allowed to cool to room temperature and excess borane quenched by adding methanol (15ml) slowly. Aqueous hydrochloric acid (1M, 15ml) was added, heated to 60°C for 1h and then evaporated to a white solid. Added saturated aqueous sodium carbonate (50ml) and diethyl ether (50ml) to dissolve the solid and extracted with diethyl ether (2x 50ml). The extracts were washed with brine solution, dried, filtered and evaporated to a colourless oil (2.38g). The oil was purified by chromatography on silica eluting with diethyl ether:hexane 75:25 to give (R)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol as a colourless oil (2.23g)

iii)




15

A solution of carbon tetrabromide (3.3g, 9.96mmol) in dichloromethane (4ml) was added dropwise over 5min to a stirred solution of (R)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol (2.0g, 6.64mmol) and triphenylphosphine (2.61g, 9.96mmol) in dichloromethane (40ml) at room temperature under nitrogen. After 30min, the reaction solution was washed with saturated aqueous sodium bicarbonate (50ml). The dichloromethane layer was dried, filtered and evaporated to a red liquid (8.5g). Trituration with diethyl ether (40ml) crystallised triphenylphosphine oxide that was then removed by filtration. The filtrate was evaporated to a yellow oil and was purified by chromatography on silica eluting with ethyl acetate:hexane 20:80 to give a colourless oil of (2R)-2-[(S)-bromo(3-fluorophenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(3-fluorophenyl)methyl]-4-benzylmorpholine (0.811g, 34%).


-50-

i)



A solution of lithium diisopropylamide (2M in heptane, 16.9ml) was added dropwise over 15min to a stirred solution of 4-benzyl-morpholin-3-one (5.0g, 26mmol) and 3-fluorobenzaldehyde (3.55g, 28.6mmol) in dried tetrahydrofuran (60ml) cooled to  $-70^{\circ}\text{C}$  under nitrogen atmosphere. After 1h at  $-70^{\circ}\text{C}$ , the reaction mixture was quenched with aqueous ammonium chloride (100ml) and extracted with ethyl acetate (100ml). The extracts were washed with 2M aqueous hydrochloric acid (2x 50ml), brine solution (100ml) and dried over sodium sulphate. After filtration, the solution was evaporated and the residual oil purified by chromatography on silica eluting with ethyl acetate:hexane 70:30 then ethyl acetate to give diastereomer 1 (2R)-2-[(S)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(R)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one as a solid (3.8g) followed by diastereomer 2 (2R)-2-[(R)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(S)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one as an oil (2.13g). Diastereomer 1 was recrystallised from ethyl acetate (25ml) n-hexane (100ml) to give white needles (2.62g, 32%).

ii)




20

A solution of borane in tetrahydrofuran (1M, 30.7ml) was added dropwise to a stirred solution of diastereomer 1 (2R)-2-[(S)-(3-fluorophenyl)(hydroxy)methyl]-4-

-49-


benzylmorpholine and 2(S)-2-((S)-[4-chlorophenyl][2-methoxyphenyl]thio)methyl)-4-benzylmorpholine (610mg, 1.39mmol) in dichloromethane (8ml) at room temperature under nitrogen. After 3h, the suspension was filtered and the filtrate evaporated. The residue was dissolved in methanol (10ml) and heated to 60°C for 1h. The solution was evaporated and the solid residue crystallised from isopropanol (5ml) diethyl ether (10ml) to give a white solid (441mg, 82%). The racemic hydrochloride salt was converted to the free base by stirring in dichloromethane (20ml) and aqueous sodium hydroxide (1M, 20ml). The dichloromethane layer was separated, dried, filtered and evaporated to a colourless oil (403mg). Chiral preparative chromatography (Chiralcel-OD, heptane:ethanol:dimethylethylamine 50:50:0.2) was used to isolate the first eluting enantiomer Rt 9.3min as an oil. This was redissolved in diethylether and treated with ethereal hydrogen chloride to give the title product (2R)-2-((R)-[4-chlorophenyl][2-methoxyphenyl]thio)methyl)morpholine hydrochloride as a solid (159mg, 36%, mp 238-241°C), NMR (DMSO) 9.31 (2H, br. s), 7.32 (4H, dd), 7.07-7.20 (2H, m), 6.91 (1H,d), 6.76 (1H,t), 4.67 (1H, d), 4.0-4.1 (2H, br d), 3.78 (3H, s), 3.72 (1H, t), 3.15 (1H, d), 2.95-3.1 (3H, m) LCMS:  $m/z$  350  $[M+H]^+$  @ Rt 3.8 min

**EXAMPLE 13****(2R)-2-((R)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl)morpholine****hydrochloride**

-48-

bromo(4-chlorophenyl)methyl]-4-benzylmorpholine (1.17g) that crystallised to a pink solid on standing.

iv)




5

Cesium carbonate (667mg, 2.05mmol) was added to a stirred solution of (2R)-2-[(S)-bromo(4-chlorophenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(4-chlorophenyl)methyl]-4-benzylmorpholine (651mg, 1.71mmol) and 2-methoxybenzenethiol (287mg, 2.05mmol) in dry dimethylformamide (3ml). The suspension was heated to 90°C for 1h. The cooled reaction mixture was diluted with iced water, 2M aqueous sodium hydroxide (1ml) and extracted with diethyl ether (15ml). The extracts were washed with brine solution, dried, filtered and evaporated to a yellow oil (0.89g). The crude product was purified by chromatography on silica eluting with ethyl acetate:heptane 1:4 to give 2(R)-2-((R)-[4-chlorophenyl]thio)methyl)-4-benzylmorpholine and 2(S)-2-((S)-[4-chlorophenyl]thio)methyl)-4-benzylmorpholine as a pale yellow oil (619mg, 82%)

10

15

v)




20

Alpha-chloroethyl chloroformate (0.3ml, 2.78mmol) was added to a gently stirred suspension of polystyrene supported diisopropylethylamine (Argonaut, 390mg, 1.39mmol) and 2(R)-2-((R)-[4-chlorophenyl]thio)methyl)-4-benzylmorpholine

benzylmorpholin-3-one and (2S)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one (2.40g 7.24mmol) in dried tetrahydrofuran (30ml) at room temperature under nitrogen causing effervescence. The solution was heated to 60°C for 2h, allowed to cool to room temperature and excess borane quenched by adding methanol (14ml) slowly. Aqueous hydrochloric acid (1M, 14ml) was added, heated to 60°C for 1h and then evaporated to a white solid. Added saturated aqueous sodium carbonate (50ml) and diethyl ether (50ml) to dissolve the solid and extracted with diethyl ether (2x 50ml). The extracts were washed with brine solution, dried, filtered and evaporated to a colourless oil (2.38g). The oil was purified by chromatography on silica eluting with diethyl ether:hexane 75:25 to give (R)-[4-chlorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[4-chlorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol as a colourless oil (2.08g)


iii)



A solution of carbon tetrabromide (2.82g, 8.5mmol) in dichloromethane (3ml) was added dropwise over 10min to a stirred solution of (R)-[4-chlorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[4-chlorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol (1.80g, 5.67mmol) and triphenylphosphine (2.23g, 8.5mmol) in dichloromethane (40ml) at room temperature under nitrogen. After 30min, the reaction solution was washed with saturated aqueous sodium bicarbonate (50ml). The dichloromethane layer was dried, filtered and evaporated to a red liquid (8.5g). Trituration with diethyl ether (20ml) crystallised triphenylphosphine oxide that was then removed by filtration. The filtrate was evaporated to a yellow oil and was purified by chromatography on silica eluting with ethyl acetate:hexane 20:80 to give a colourless oil of (2R)-2-[(S)-bromo(4-chlorophenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-


-46-

i)



A solution of lithium diisopropylamide (2M in heptane, 18.2ml) was added dropwise over 20min to a stirred solution of 4-benzyl-morpholin-3-one (5.0g, 26mmol) and 4-chlorobenzaldehyde (4.41g, 31.4mmol) in dried tetrahydrofuran (60ml) cooled to -70°C under nitrogen atmosphere. After 1h at -70°C, the reaction mixture was quenched with aqueous ammonium chloride (100ml) and extracted with ethyl acetate (100ml). The extracts were washed with 2M aqueous hydrochloric acid (100ml), brine solution (100ml) and dried over sodium sulphate. After filtration, the solution was evaporated and the residual oil purified by chromatography on silica eluting with ethyl acetate:hexane 70:30 then ethyl acetate to give diastereomer 1 (2R)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one as a solid (2.64g) followed by diastereomer 2 (2R)-2-[(R)-(4-chlorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one as an oil (1.46g). Diastereomer 1 was recrystallised from ethyl acetate (25ml) n-hexane (100ml) to give white needles (2.47g, 29%)

ii)



20

A solution of borane in tetrahydrofuran (1M, 29ml) was added dropwise to a stirred solution of diastereomer 1 (2R)-2-[(S)-(4-chlorophenyl)(hydroxy)methyl]-4-




-45-


dry dichloromethane (70 ml) was added  $\alpha$ -chloroethyl chloroformate (2.93 ml, 28.6 mmol, 3 eq.) at room temperature and under nitrogen. The mixture was heated at 40°C for 1.5 hours then left to stir at room temperature overnight. The reaction mixture was filtered and concentrated *in vacuo* to give a pale orange liquid. This was taken up in methanol (70 ml) and heated at 40°C for 2 hours. A white solid crashed out of the solution which was purified by SCX chromatography (eluent: ammonia/methanol 1/1 [v/v]). After evaporation *in vacuo* the product was obtained as a pale yellow oil (3.13 g, 99%); MW 331.50;  $C_{18}H_{21}NOS_2$ ;  $^1H$  NMR ( $CDCl_3$ ): 7.03-7.15 (6H, m), 6.93-6.99 (2H, m), 6.74 (1H, td, 7.3 Hz, 1.5 Hz), 4.31 (1H, d, 7.8 Hz), 3.95 (1H, br. d, 12.1 Hz), 3.83 (1H, td, 8.1 Hz, 3.8 Hz), 3.59 (1H, td, 11.1 Hz, 2.8 Hz), 2.82 (1H, td, 12.1 Hz, 3.3 Hz), 2.61-2.75 (3H, m), 2.35 (3H, s), 1.73 (1H, br. s). After separation by chiral chromatography the oil was converted into its hydrochloride salt in which the pale yellow oil was taken up in isopropanol (~200 ml) and filtered. Addition of hydrogen chloride (19 ml of a 1M solution in diethyl ether, 19 mmol) gave a white precipitate to which further diethyl ether (~50 ml) was added. The solid was isolated by filtration, washed with diethyl ether give the hydrochloride salt of the title product as a white solid (3.03 g); MW 367.96;  $C_{18}H_{22}ClNOS_2$ ;  $^1H$  NMR ( $CDCl_3$ ): 9.94 (2H, br. s), 7.06-7.18 (6H, m), 6.94-7.03 (2H, m), 6.78 (1H, t, 6.8 Hz), 4.24-4.32 (1H, m), 4.20 (1H, d, 5.8 Hz), 3.89-4.06 (2H, m), 3.18 (2H, br. t, 11.9 Hz), 2.99 (2H, br. s), 2.37 (3H, s); LCMS (10 minutes method): m/z 332 [M-Cl]<sup>+</sup> @ Rt 5.07 min.

**EXAMPLE 12**

(2R)-2-((R)-[4-chlorophenyl]thio)methylmorpholine hydrochloride




-44-



- To a solution of (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine (4.0 g, 11.55 mmol) and 2-methylsulphenyl-thiophenol (1.2 eq, 2.17 g, 13.86 mmol) in anhydrous DMF (35 ml) at room temperature under nitrogen was added cesium carbonate (1.18 eq., 14.04 g, 13.63 mmol). The mixture was heated at 50°C for 1.5 hours; allowed to cool to room temperature, taken up in methanol and treated with SCX-2 (100 g). The SCX-2 was washed with methanol. The product was obtained as a white solid (4.92 g) after SCX chromatography (eluent: ammonia/methanol 1/1 [v/v]) and removal of solvents *in vacuo*.
- 10 Purification by flash column chromatography (eluent: ethyl acetate/isohehexane gradient 10/90 to 30/70 [v/v]) gave a white solid (4.04 g, 86%); MW 421.63; C<sub>27</sub>H<sub>25</sub>NOS<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.03-7.15 (6H, m), 6.93-6.99 (2H, m), 6.74 (1H, td, 7.3 Hz, 1.5 Hz), 4.31 (1H, d, 7.8 Hz), 3.95 (1H, br. d, 12.1 Hz), 3.83 (1H, td, 8.1 Hz, 3.8 Hz), 3.59 (1H, td, 11.1 Hz, 2.8 Hz), 2.82 (1H, td, 12.1 Hz, 3.3 Hz), 2.61-2.75 (3H, m), 2.35 (3H, s), 1.73 (1H, br. s); LCMS (6 minutes method): m/z 422 [M+H]<sup>+</sup> @ Rt 3.36 min.
- 15

ii) (2R)-2-[(R)-{[2-(methylthio)phenyl]thio}(phenyl)methyl]morpholine hydrochloride




- 20 To a suspension of polymer supported Hunig's base (5.02 g) and (2R)-2-[(R)-[phenyl]{[2-methylthiophenyl]thio}methyl]-4-benzylmorpholine and (2S)-2-[(S)-[phenyl]{[2-methylthiophenyl]thio}methyl]-4-benzylmorpholine (4.02 g, 9.49 mmol) in

$C_{25}H_{27}NO_2S$ ;  $^1H$  NMR ( $CDCl_3$ ): 7.01-7.26 (12H, m), 6.58-6.63 (2H, m), 4.39 (1H, d, 7.2 Hz), 3.86-3.91 (2H, m), 3.71 (3H, s), 3.56-3.62 (1H, m), 3.42 (1H, d, 10.8 Hz); 3.21 (1H, d, 10.8 Hz), 2.46-2.52 (2H, m), 2.01-2.11 (2H, m); LCMS (10 minutes method):  $m/z$  406  $[M+H]^+$  @  $R_T$  6.09 min.

5

ii) (2*R*)-2-[(*R*)-{[2-(Methyloxy)phenyl]thio}(phenyl)methyl]morpholine hydrochloride



Reaction of (2*S*)-2-[(*S*)-{[2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine and (2*R*)-2-[(*R*)-{[2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine (100 mg, 0.25 mmol) following the method in example 1(iv) gave a viscous yellow oil (60 mg, 77% yield) from which the product was obtained after chiral separation on a Chiralcel OJ semi-preparative column. LC purity = 100%; MW 315.44;  $C_{18}H_{21}NO_2S$ ;  $^1H$  NMR ( $CDCl_3$ ): 7.14-7.34 (7H, m), 6.74-6.84 (2H, m), 4.50 (1H, d, 8.2 Hz), 4.10 (1H, d, 10.9 Hz), 3.85-4.00 (4H, m), 3.74 (1H, dt, 1.4 Hz, 11.3 Hz), 2.82-3.02 (2H, m), 2.66-3.02 (3H, m); LCMS (10 minutes method):  $m/z$  316  $[M+H]^+$  @  $R_T$  4.87 min. This was converted to its hydrochloride salt.

## 20 EXAMPLE 11

(2*R*)-2-[(*R*)-{[2-(methylthio)phenyl]thio}(phenyl)methyl]morpholine hydrochloride

i) (2*R*)-2-[(*R*)-[phenyl]{[2-methylthiophenyl]thio}methyl]-4-benzylmorpholine and (2*S*)-2-[(*S*)-[phenyl]{[2-methylthiophenyl]thio}methyl]-4-benzylmorpholine

-42-


m), 7.01 (2H, d, 3.8 Hz), 6.87-6.93 (1H, m), 4.07 (1H, d, 8.1 Hz), 3.92-3.97 (1H, m), 3.74-3.80 (1H, m), 3.59 (1H, td, 11.4 Hz, 3.0 Hz), 2.80 (1H, td, 12.4 Hz, 3.3 Hz), 2.71 (1H, br. d, 12.1 Hz), 2.63-2.54 (4H, m), 1.64 (1H, br. s), 1.04 (3H, t, 7.6 Hz); LCMS (10 minutes method): m/z 314 [M+H]<sup>+</sup> @ Rt 5.92 min. (2R)-2-[(R)-[2-

- 5 ethylphenyl]thio](phenyl)methyl]morpholine was converted into its hydrochloride salt. MW 349.93; C<sub>19</sub>H<sub>23</sub>NOS.HCl; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 10.10 (2H, br. s), 7.13-7.28 (8H, m), 7.02-7.08 (1H, m), 4.36 (1H, br. s), 4.01-4.17 (3H, br. m), 3.16-3.31 (2H, br. m), 2.92-3.09 (2H, br. m), 2.71 (2H, q, 7.7 Hz), 1.15 (3H, t, 7.2 Hz).

# 10 EXAMPLE 10


## (2R)-2-[(R)-{2-(Methyloxy)phenyl]thio}(phenyl)methyl]morpholine hydrochloride

- i) (2S)-2-[(S)-{2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine and (2R)-2-[(R)-{2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine
- 15 4-(phenylmethyl)morpholine




- Compound (2S)-2-[(S)-{2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine and (2R)-2-[(R)-{2-(Methyloxy)phenyl]thio}(phenyl)methyl]-4-(phenylmethyl)morpholine was obtained from 2-methoxy thiophenol (74 µl, 0.574 mmol) and (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine (181 mg, 0.522 mmol) following the method in example 8(vi) in which the reaction was heated at 95°C for 2.5h. After purification by flash column chromatography (eluent: ethyl acetate/hexane gradient 15/85 to 25/75 [v/v]) the product was obtained as a viscous yellow oil (175 mg, 83% yield); MW 405.56;
- 20
- 25

-41-



Compound (2S)-2-[(S)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine and (2R)-2-[(R)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine was obtained from 2-ethyl-thiophenol (160 mg, 1.16 mmol) and (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine (200 mg, 0.58 mmol) following a modification of the method described in example 8(vi) in which the reaction mixture was heated to 95°C for 2 hours. After purification by flash column chromatography (eluent: ethyl acetate/hexane 9/1 [v/v]) the product was obtained as a white solid (152 mg, 65 % yield); MW 403.59; C<sub>26</sub>H<sub>29</sub>NOS; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 6.96-7.40 (14H, m), 4.22 (1H, d, 7.2 Hz), 3.96-4.01 (2H, m), 3.72 (1H, td, 11.1 Hz, 2.2 Hz), 3.52 (1H, d, 13.1 Hz), 3.32 (1H, d, 13.1 Hz), 2.68 (2H, q, 7.7 Hz), 2.59 (2H, br d, 11.7 Hz), 2.06-2.21 (2H, m), 1.12 (3H, t, 7.2 Hz); LCMS (2.5 minute method) m/z 404 [M+H]<sup>+</sup> @ Rt 1.49 min.


ii) (2R)-2-[(R)-[(2-ethylphenyl)thio](phenyl)methyl]morpholine hydrochloride



Reaction of (2S)-2-[(S)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine and (2R)-2-[(R)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine following the method in example 1(iv) gave a viscous yellow oil (213.3 mg, 86% yield) from which the title product was obtained after chiral separation on chiral OD semi-preparative column; LC purity = 100% (UV254nm) / 100% (ELS); MW 313.47; C<sub>19</sub>H<sub>23</sub>NOS; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.17 (1H, d, 7.6 Hz), 7.12-7.05 (5H,

BEST AVAILABLE COPY

-40-



- To a solution of (*R*)-phenyl[(2*R*)-4-(phenylmethyl)morpholin-2-yl]methanol (11.2g, 39.58 mmol) in anhydrous chloroform (400 ml) under nitrogen was added PPh<sub>3</sub>Br<sub>2</sub> (33.41g, 79.15 mmol). The reaction mixture was heated at 60°C overnight. The mixture was allowed to cool to room temperature then washed with saturated aqueous sodium carbonate solution, dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The resulting residue was purified by flash chromatography on silica (eluent: ethyl acetate:isohexane 1:4) to give a pale yellow oil. Trituration with isohexane gave (2*R*)-2-[(*S*)-bromo(phenyl)methyl]-4-(phenylmethyl)morpholine as a colourless solid (8.54g, 62%);
- 10 MW 346.27; C<sub>18</sub>H<sub>20</sub>BrNO; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.14-7.39 (10H, m), 4.83 (1H, d, 7.4 Hz), 4.01 (1H, br. t, 8.3 Hz), 3.73 (1H, br. d, 11.1 Hz), 3.60-3.48 (2H, m), 3.39 (1H, d, 12 Hz), 3.20 (1H, d, 11.4 Hz), 2.50 (1H, d, 10.4 Hz), 2.07 (2H, t, 10.9 Hz); LCMS: (6 min method) *m/z* 346 [M]<sup>+</sup> @ Rt 2.51 min.
- 15 (vi) (2*R*)-2-[(*S*)-bromo(phenyl)methyl]-4-(phenylmethyl)morpholine can then be converted to the title product (2*R*)-2-[(*R*)-[phenyl][2-trifluoromethylphenylthio]methyl]morpholine hydrochloride using the above procedure in example 8 Method 1 (v) and (vi).

## 20 EXAMPLE 9


### (2*R*)-2-[(*R*)-[(2-ethylphenyl)thio](phenyl)methyl]morpholine

- i) (2*S*)-2-[(*S*)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine and (2*R*)-2-[(*R*)-[(2-ethylphenyl)thio](phenyl)methyl]-4-(phenylmethyl)morpholine

-39-

Ultra pure water was added (125.4 L) and the mixture was stirred overnight at RT and cooled down to about 0 °C for 1 hour. The precipitate was filtered and rinsed with a cooled water/isopropanol 50/50 v/v solution (76.6 kg). The wet precipitate was dried under vacuum at Tjack = 35°C for 96 hours to obtain the title compound as an off-white powder with 59 % overall yield. The title compound may be resolved by the fractional crystallisation process described above.

(iii) (R)-phenyl[(2R)-4-(phenylmethyl)morpholin-2-yl]methanol



To a stirred solution of (+)-DIP chloride (49.6 g, 155 mmol) in dry THF (150 ml) under nitrogen was added (2R)-(4-benzyl-morpholin-2-yl)-phenyl-methanone (16.54g, 58.89 mmol) in one portion. The reaction mixture was stirred at room temperature for 18 hours. The mixture was evaporated *in vacuo* and the crude oil taken up in methanol and absorbed onto 250g SCX-2 ion exchange resin. After elution of borane residues with methanol the product was eluted with 2M ammonia in methanol. Removal of solvent *in vacuo* yielded the product as yellow oil. (11.23g, 67%); MW 283.37; C<sub>18</sub>H<sub>21</sub>NO<sub>2</sub>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.32-7.45 (10H, m), 4.67 (1H, d, 7.3 Hz), 4.03 (1H, dt, 11.4 Hz, 2.7 Hz), 3.86-3.73 (2H, m), 3.64 (1H, d, 13.2 Hz), 3.39 (1H, d, 13.2 Hz), 3.30 (1H, br. s), 2.68 (1H, d, 12.7 Hz), 2.56 (1H, d, 10.9 Hz), 2.28-2.15 (2H, m); LCMS: m/z 284 [M+H]<sup>+</sup> @ Rt 0.95 min.

(v) (2R)-2-[(S)-bromo(phenyl)methyl]-4-(phenylmethyl)morpholine

BEST AVAILABLE COPY

-38-

aqueous layer (176 kg) was separated after 35 minutes of post-stirring allowing the mixture to reach 15 °C and the toluene layer was washed with ultra pure water (142.5 L) and the aqueous layer (162 kg) was separated. The organic layer was then concentrated under reduced pressure (150 mbars) maintaining  $T_{\text{mass}} \leq 60$  °C in order to distill 162 kg of toluene. The filtrates were then diluted with toluene (114 L) and treated with SiO<sub>2</sub> (Merck silica gel 60, 0.063-0.1 mm, 74.1 kg) under agitation at room temperature for 1.25 h. SiO<sub>2</sub> was filtered and rinsed with toluene (2x114 L). Then, the filtrates were concentrated under reduced pressure (150 mbars) maintaining  $T_{\text{mass}} \leq 60$  °C in order to distill 351.8 kg of toluene (KF : 0.01 % w/w H<sub>2</sub>O).

10 The solution of 4-Benzyl-morpholine-2-carbonitrile (169.2 kg) was diluted with toluene (157 L) and was cooled to 0°C and phenylmagnesiumchloride (25 wt. % solution in THF, 213 kg, 389 moles, 1.36 molar equiv.) was slowly added (over 3.5 h) to the reaction mixture, maintaining the temperature at  $-3$  °C  $\leq T_{\text{mass}} \leq 7$  °C. The reaction mixture was post-stirred for 2 hours at  $T_{\text{mass}} \approx 0$ °C. Then, the quench was performed by adding acetic acid (8.55 L,  $T_{\text{mass}} = 5 \rightarrow 17.2$  °C), post stirring 10 minutes and cooling to 5 °C before adding an acetic acid / water mixture (229 L, 33/67 v/v). During the quench, addition was performed at such a rate that  $T_{\text{mass}}$  did not exceed 20°C (typical  $T_{\text{mass}} = 4.6$  °C to 10.4 °C). The mixture was post-agitated overnight at RT and the aqueous layer (285.8 kg) was extracted.

20 The toluene layer was cooled to 0°C and a 5 N NaOH aqueous solution (420.1 kg) was slowly added maintaining the temperature at  $-2.4$  °C  $\leq T_{\text{mass}} \leq 11$  °C. The reaction mixture was post-stirred for 1h and the aqueous layer (494.8 kg) was extracted. The toluene layer was concentrated under reduced pressure (50 mbars) maintaining  $T_{\text{mass}} \leq 60$  °C in order to distill 356.2 kg of toluene and isopropanol (180.4 kg) was added. The toluene was stripped off under reduced pressure (100 mbars) maintaining  $T_{\text{mass}} \leq 60$  °C in order to distill 186.4 kg of toluene and isopropanol (135 kg) was added again to the mixture. A last distillation of toluene was performed under reduced pressure (50 mbars) maintaining  $T_{\text{mass}} \leq 60$  °C in order to distill 131 kg of toluene and isopropanol (49.4 kg) was finally added to the mixture and the solution was stirred at RT until crystallization (17 minutes).



-37-

5 filtered. The organic layer of the mother liquors, which contains impurities, was eliminated. The filtration cake was then washed with methylene chloride (700ml). This liquor was charged in the reactor with the acid aqueous layer. Treatment of the hydrochloride salt: After drying under vacuum, 164.4 g of the hydrochloride  
10 contaminated with  $MgCl_2$  were suspended in a biphasic mixture of water/methylenechloride (500ml/800ml). The suspension was basified with aqueous sodium hydroxide (75 ml of a 30% solution) under ice bath cooling.  $Mg(OH)_2$  precipitated and the aqueous layer was extracted with methylene chloride. The organic layers are filtered on a bed of Celite 512 after adding some Celite to the layers  
15 themselves. The filtered organic phase was dried over  $MgSO_4$  and evaporated to dryness. The ketone crystallizes readily on standing (132.4g; 70%). Treatment of the mother liquors: The combined organic phases were washed with aqueous sodium hydroxide (750ml of a 2N solution). Celite 512 (160 g) was added to the suspension which was then filtrated through bed of Celite. The aqueous layer was separated and extracted with  
20 methylene chloride. The combined organic phases were dried over  $MgSO_4$  and evaporated to dryness to provide 35.8 g of product enriched with unreacted nitrile. This fraction could be further purified by percolation on  $SiO_2$ . (2S)-(4-benzyl-morpholin-2-yl)-phenyl-methanone and (2R)-(4-benzyl-morpholin-2-yl)-phenyl-methanone were separated using preparative chiral chromatography. Alternatively, the two enantiomers  
25 may be separated by fractional crystallization from acetonitrile using from 0.55 to 1 equivalent of dibenzoyltartaric acid to generate diastereoisomeric salts of the title compound. The crystals may be collected by filtration and neutralized with 30% NaOH to afford the optically enriched title compound.


25 The title compound may also be prepared using the following one-pot synthesis. A 1600 L GL reactor under  $N_2$  was successively loaded with 2-chloroacrylonitrile (33.2 kg, 379 moles) and toluene (114 L) at 21°C. Then, N-benzylethanolamine (57 kg, 377 moles) was added and the reaction mixture was post-agitated at room temperature for about 17 h. Then, the mixture was diluted with toluene (336 L), cooled down to -12.4  
30 °C and potassium t-butoxide (42.3 kg, 377 moles) was added in portions (10) maintaining -13.7 °C ≤ T<sub>mass</sub> ≤ -2.8 °C. The mixture was post-agitated at about 0°C for 2.5 h, quenched by adding ultra pure water (142.5 L) maintaining 2.1 °C ≤ T<sub>mass</sub> ≤ 8.7 °C. The

BEST AVAILABLE COPY

-36-

A one-liter reactor with mechanical stirring, cooled by ice bath, was charged with *N*-benzylethanolamine (172.2 g, 1.14 mol). 2-Chloroacrylonitrile (100g, 1.14 mol) was added dropwise over a period of 2 minutes. The temperature was kept between 23°C and 29°C using an ice bath, progressively replaced by a water bath at 15°C. After stirring at room temperature over night the mixture was dissolved in THF and transferred into a 2l reactor cooled to -5°C by an ice/NaCl bath. The total volume of THF equalled 1.35l. Potassium *tert*-butoxide (148g, 1.1 eq.) was added in portions over 1 hour, while maintaining the temperature at 0±2°C. After 1 hour stirring at 0°C the mixture was quenched by saturated NaHCO<sub>3</sub> (500ml). The aqueous layer was extracted with diethyl ether. The organic layers were dried over MgSO<sub>4</sub> and evaporated to dryness. After percolation of the 250 g dry residue on 1 kg SiO<sub>2</sub> (eluent: ethyl acetate/*n*-heptane gradient 5/95 to 80/100 [v/v]) 4-benzyl-morpholine-2-carbonitrile was obtained as a clear oil (149.8g, 65%).

(ii) (2*S*)-(4-Benzyl-morpholin-2-yl)-phenyl-methanone and (2*R*)-(4-Benzyl-morpholin-2-yl)-phenyl-methanone



A 3l double jacket reactor was charged with 4-benzyl-morpholine-2-carbonitrile (135.05 g; 1eq) and dry diethyl ether (1.4l). Alternatively, toluene may be used in place of diethyl ether. When T<sub>j</sub>=0°C and T<sub>m</sub>=1°C (T<sub>j</sub> = temperature of the jacket, T<sub>m</sub> = temperature of the mass), phenyl magnesium chloride (2M sol. in THF, 360ml, 1.08 equiv) was added dropwise over 1 hour. T<sub>m</sub> rose to 4°C and came back to 2°C at the end of the addition. T<sub>m</sub> was progressively raised to 17.5°C within 45 minutes and the mixture stirred at this temperature for another 45 minutes. The reactor was cooled down to T<sub>m</sub>=2°C and T<sub>j</sub>=0°C (75 minutes) and hydrochloric acid (700ml of 5N solution) was added in two portions. T<sub>m</sub> rose to 33°C. After some minutes, the hydrochloride salt of the ketone crystallised. When T<sub>m</sub>=T<sub>j</sub>=room temperature, the triphasic suspension was

trifluoromethylphenyl]thio)methyl)-4-benzylmorpholine (5.25 g, 11.84 mmol), solid supported Hunig's base (Argonaut, 3.56 mmol/g, 6.64 g, 23.67 mmol, 2 eq.) and  $\alpha$ -chloroethyl chloroformate (3.83 ml, 35.51 mmol, 3 eq.) in anhydrous dichloromethane (75 ml) at 40°C following the method described in example 1(iv). After evaporation of the methanol solution a light brown solid (5.60 g) was obtained which was recrystallised from iso-propanol to give the hydrochloride salt as fine white needles. The hydrochloride salt was suspended in ethyl acetate and washed with an aqueous solution of sodium hydroxide (50 ml of a 1M solution). The organic layer was washed with brine, dried over  $\text{MgSO}_4$  and concentrated *in vacuo* to yield the free amine as a colourless oil (3.10 g, 74% yield); MW 353.41;  $\text{C}_{18}\text{H}_{18}\text{F}_3\text{NOS}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 7.46 (1H, d, 7.7 Hz), 7.24 (1H, d, 7.3 Hz), 7.05-7.2 (7H, m), 4.28 (1H, d, 7.7 Hz), 3.92 (1H, d, 11.4 Hz), 3.80 (1H, q, 7.0 Hz), 3.58 (1H, dt, 1.82 Hz, 11.4 Hz), 2.69-2.87 (2H, m), 2.59 (2H, d, 6.0 Hz), 2.13-1.90 (1H, br s); LCMS (10 minutes method):  $m/z$  354  $[\text{M}+\text{H}]^+$  @ Rt 5.26 min.


A sample of the racemic free base (1.384g) was separated by preparative chiral chromatography (Chiralpak-OJ, heptane: isopropanol: dimethylethylamine 70: 30: 0.2) to give the first eluting enantiomer Rt 9.5min (0.57g) as an oil. Redissolved in diethyl ether (20ml) and treated with ethereal hydrogen chloride (2M 0.8ml) to give a white solid (566mg, mp 240-1°C) of the title product (2R)-2-((R)-[phenyl][2-trifluoromethylphenylthio]methyl)morpholine hydrochloride.

The second eluting enantiomer Rt 15.8min was obtained as an oil (0.55g) and similarly converted to the hydrochloride salt (2S)-2-((S)-[phenyl][2-trifluoromethylphenylthio]methyl)morpholine hydrochloride (556mg mp 244-5°C). A sample (20mg) was crystallised from isopropanol (2ml) allowing the solvent to evaporate slowly over several weeks. The crystals were analysed by xray crystallography to confirm the absolute stereochemistry as (S,S) for the second eluting enantiomer, data is listed in tables 1-6 herein.

## Method 2


(i) 4-benzyl-morpholine-2-carbonitrile

-34-



To a stirred solution of 2-trifluoromethylthiophenol (2.469g, 13.86mmol) and (2R)-2-[(S)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine (4.0g, 11.55mmol) in anhydrous DMF (60ml) at room temperature under nitrogen was added cesium carbonate (4.14g, 12.71g). The reaction mixture was heated at 95°C for 1h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, then washed sequentially with water, brine, dried over magnesium sulphate, filtered and evaporated to a brown oil. The oil was purified by flash column chromatography (eluent: hexane/ethyl acetate gradient 100 to 90/10 [v/v]) to give a yellow oil (4.83 g, 94% yield); MW 444; C<sub>25</sub>H<sub>24</sub>F<sub>3</sub>NOS; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.60 (1H, dd, 7.2 Hz, 1.4 Hz), 7.17-7.39 (13H, m), 4.50 (1H, d, 7.2 Hz), 3.97-4.12 (2H, m), 3.73 (1H, dt, 9.7 Hz, 2.3 Hz), 3.59 (1H, d, 12.6 Hz), 3.37 (1H, d, 12.6 Hz), 2.57-2.68 (2H, m); 2.18-2.38 (2H, m); LCMS (2.5 minutes method): m/z 445 [M+H]<sup>+</sup> @ Rt 1.50 min.

vii) (2R)-2-((R)-[phenyl][2-trifluoromethylphenylthio]methyl)morpholine hydrochloride



The title compound was obtained from (2R)-2-((R)-[phenyl][2-trifluoromethylphenylthio]methyl)-4-benzylmorpholine and (2S)-2-((S)-[phenyl][2-trifluoromethylphenylthio]methyl)-4-benzylmorpholine.


and washed with saturated aqueous sodium hydrogencarbonate solution (150 ml), brine (150 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo* to give an orange oil (42.0 g). To the orange oil was added diethyl ether (200 ml) and the resulting suspension was sonicated for 30 minutes. The solvent was decanted and the process repeated with a further portion of diethyl ether (200 ml). The combined ethereal extracts were concentrated *in vacuo* to yield an orange solid (22.0 g) which was purified by flash column chromatography (10% EtOAc : 89.5% Hexane, 0.5% Triethylamine) to give a white solid (7.20 g, 58% yield). Alternative Work-up: The reaction mixture was poured onto a silica (160 g) filtration pad which was washed using suction with dichloromethane (14 x 250 ml). Stripping this filtrate *in vacuo* gave crude product (16.0 g, 131% uncorrected). This was purified by flash column chromatography (5% EtOAc : 94.5% Hexane : 0.5% Triethylamine to 10% EtOAc : 89.5% Hexane : 0.5% Triethylamine) to give a white solid (6.05 g, 50% yield); MW 346.27; C<sub>18</sub>H<sub>20</sub>BrNO; R<sub>f</sub> 0.76 (70% EtOAc, 30% hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.39-7.14 (10H, m), 4.83 (1H, d, 7.4 Hz), 4.01 (1H, br. t, 8.3 Hz), 3.73 (1H, br. d, 11.1 Hz), 3.60-3.48 (2H, m), 3.39 (1H, d, 12 Hz), 3.20 (1H, d, 11.4 Hz), 2.50 (1H, d, 10.4 Hz), 2.07 (2H, t, 10.9 Hz); LCMS: m/z 348/346 [M+H]<sup>+</sup> @ Rt 1.20 min (single major peak). This reaction was performed on scales from 100 to 400 mg (yield range = 60 to 93%).

A sample of racemic (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine (6.02g) was separated by preparative chiral chromatography (Chiralcel-AD 1kg column, ethanol: dimethylethylamine 100: 0.3) to give the first eluting enantiomer Rt 23.4min as an off-white solid (2.89g) of (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and the second eluting enantiomer Rt 28.9min as an off-white solid (2.89g) of (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine (2.21g)

vi) (2R)-2-((R)-[phenyl][{2-trifluoromethylphenyl}thio)methyl]-4-benzylmorpholine and (2S)-2-((S)-[phenyl][{2-trifluoromethylphenyl}thio)methyl]-4-benzylmorpholine


-32-

(iv) (R)-[(2S)-4-benzylmorpholinyl](phenyl)methanol and (S)-[(2R)-4-benzylmorpholinyl](phenyl)methanol



Using the procedure described in Example 8(iii) starting from (2R)-4-benzyl-2-[(R)-hydroxy(phenyl)methyl]-morpholin-3-one and (2S)-4-benzyl-2-[(S)-hydroxy(phenyl)methyl]-morpholin-3-one (135 mg, 0.51 mmol) the reaction and subsequent purification yielded a viscous oil (98 mg, 68% yield); MW 283.37;  $C_{18}H_{21}NO_2$ ; Rf 0.52 (100% EtOAc);  $^1H$  NMR (CDCl<sub>3</sub>): 7.28-7.17 (10H, m), 4.80 (1H, d, 4.0 Hz), 3.88 (1H, dt, 11.4 Hz, 3.0 Hz), 3.72 (1H, m), 3.68-3.61 (1H, m), 3.50 (1H, d, 13 Hz), 3.25 (1H, d, 13 Hz), 2.52 (2H, br. t, 12.0 Hz), 2.17 (1H, t, 11 Hz), 2.08 (1H, td, 11 Hz, 3.0 Hz), OH not observed; LCMS: m/z 284 [M+H]<sup>+</sup> @ Rt 0.98 min (single major peak). This reaction was performed on scales from 100 to 400 mg (yield range = 60 to 93%).

(v) (2R)-4-benzyl-2-[(S)-bromo(phenyl)methyl]morpholine and (2S)-4-benzyl-2-[(R)-bromo(phenyl)methyl]morpholine




To a solution of (S)-[(2S)-4-benzylmorpholinyl](phenyl)methanol and (R)-[(2R)-4-benzylmorpholinyl](phenyl)methanol (10.27 g, 36.29 mmol) in anhydrous dichloromethane (150 ml) under nitrogen at room temperature was added freshly recrystallised triphenylphosphine (1.4 eq., 13.310 g, 50.80 mmol) followed by carbon tetrabromide (1.4 eq., 16.849 g, 50.80 mmol) as a solution in anhydrous dichloromethane (50 ml). After 15 minutes the reaction mixture was diluted with dichloromethane (100 ml)

-31-

1.9 Hz), 3.77 (1H, dt, 11.0 Hz, 3.5 Hz), 3.50 (1H, dt, 12.0 Hz, 4.0 Hz), 3.16 (1H, br. d, 12.0 Hz); LCMS:  $m/z$  298  $[M+H]^+$  @ Rt 1.24 min (single major peak).

(iii) (S)-[(2S)-4-benzylmorpholinyl](phenyl)methanol and (R)-[(2R)-4-benzylmorpholinyl](phenyl)methanol



5

To a solution of (2R)-4-benzyl-2-[(S)-hydroxy(phenyl)methyl]morpholin-3-one and (2S)-4-benzyl-2-[(R)-hydroxy(phenyl)methyl]morpholin-3-one (326 mg, 1.1 mmol) in anhydrous THF (5 ml) under nitrogen at room temperature was slowly added a 1 M solution of borane in THF (4 eq., 4.4 ml, 4.4 mmol). The solution was stirred at 60°C for 10 2 hours. After cooling down to room temperature, dry methanol (2 ml) was slowly added to quench excess borane reagent. 1 M. Aqueous hydrochloric acid solution (2 ml) was added and the reaction mixture was heated to 60°C for 1 hour. The organic solvents were evaporated *in vacuo* and the concentrated solution was poured onto 1 M aqueous potassium carbonate solution (10 ml) and extracted with diethyl ether (2 x 20 ml). The 15 combined organic layers were washed with brine (20 ml), water (20 ml), dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The resultant oil was purified by flash column chromatography (90% hexane, 9% EtOAc, 1% NEt<sub>3</sub>) to give a viscous oil (189 mg, 60% yield); MW 283.37; C<sub>18</sub>H<sub>21</sub>NO<sub>2</sub>; R<sub>f</sub> 0.42 (90% EtOAc, 10% hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.45-7.32 (10H, m), 4.67 (1H, d, 7.3 Hz), 4.03 (1H, dt, 11.4 Hz, 2.7 Hz), 3.86-20 3.73 (2H, m), 3.64 (1H, d, 13.2 Hz), 3.39 (1H, d, 13.2 Hz), 3.30 (1H, br. s), 2.68 (1H, d, 12.7 Hz), 2.56 (1H, d, 10.9 Hz), 2.28-2.15 (2H, m); LCMS:  $m/z$  284  $[M+H]^+$  @ Rt 0.95 min (single major peak).

This reaction was performed on scales from 50 mg to 1.5 g (yield range = 50 to 84%).


25

-30-

To a stirred solution of 4-benzylmorpholin-3-one (5.02 g, 26 mmol) in anhydrous THF (25 ml) under nitrogen at -78°C was added a 2 M. solution of LDA in heptane/THF/ethylbenzene (1.5 eq., 39 mmol, 19.5 ml) over approximately 20 minutes, whilst maintaining the reaction temperature below -75°C. The resulting brown solution was stirred for a further 30 minutes at -78°C, before being slowly added over approximately 30 minutes to a solution of benzaldehyde (1.2 eq., 3.34 g, 31 mmol) in anhydrous THF (15 ml) under nitrogen at -78°C, whilst again maintaining the reaction temperature below -75°C. The resulting yellow solution was stirred at -78°C for 1 hour, before being allowed to warm to room temperature slowly over 1 hour. The reaction mixture was cautiously quenched by addition of saturated ammonium chloride solution (50 ml) and the THF was evaporated *in vacuo* from the mixture. The resulting cloudy aqueous solution was extracted with DCM (3 x 50 ml), and the organic extracts were combined, washed with brine (50 ml), dried over Na<sub>2</sub>SO<sub>4</sub> and the DCM evaporated *in vacuo* to give a thick brown oil (9.2 g), which partially crystallised on standing. The mixture of diastereoisomeric alcohols was purified and separated by flash column chromatography using gradient elution (from 10% EtOAc, 90% DCM to 20% EtOAc, 80% DCM), which gave (2R)-4-benzyl-2-[(S)-hydroxy(phenyl)methyl]morpholin-3-one and (2S)-4-benzyl-2-[(R)-hydroxy(phenyl)methyl]morpholin-3-one as light red crystals (2.461 g, 31% yield); MW 297.36; C<sub>18</sub>H<sub>19</sub>NO<sub>3</sub>; R<sub>f</sub> 0.40 (50% EtOAc, 50% hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.41-7.36 (2H, m), 7.31-7.16 (6H, m), 6.91-6.86 (2H, m), 5.14 (1H, d, J 3.5 Hz), 4.71 (1H, d, 14.5 Hz), 4.48 (1H, d, J 3.5 Hz), 4.25 (1H, d, 14.5 Hz), 4.20 (1H, br s), 3.89 (1H, ddd, 11.7 Hz, 2.5 Hz, 2.0 Hz), 3.67 (1H, dt, 11.2 Hz, 3.4 Hz), 3.16 (1H, dt, 12.0 Hz, 4.0 Hz), 2.86 (1H, br. d, 12.0 Hz); LCMS: m/z 298 [M+H]<sup>+</sup> @ Rt 1.24 min (single major peak). This reaction was performed on scales from 200 mg to 5 g (yield range 20 to 40%). (2R)-4-benzyl-2-[(R)-hydroxy(phenyl)methyl]morpholin-3-one and (2S)-4-benzyl-2-[(S)-hydroxy(phenyl)methyl]morpholin-3-one diastereoisomer was isolated as a brown solid (1.42 g) contaminated with *N*-benzylmorpholin-3-one. Trituration with EtOAc afforded the pure compound as a white solid (0.484 g, 6% yield); MW 297.36; C<sub>18</sub>H<sub>19</sub>NO<sub>3</sub>; R<sub>f</sub> 0.23 (50% EtOAc, 50% hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.61-7.55 (2H, m), 7.50-7.36 (6H, m), 7.31-7.25 (2H, m), 5.21 (1H, d, 2.3 Hz), 5.09 (1H, d, J 7.7 Hz, 2.3 Hz), 4.73 (2H, s, s Hz), 4.37 (1H, d, J 7.7 Hz), 4.01 (1H, ddd, 12.0 Hz, 2.6 Hz,





-29-



A solution of *N*-benzyl-*N*-(2-hydroxyethyl)chloroacetamide (1.0 eq., 627.7 g, 2.759 mol) in tert-butanol (0.9 L) was stirred under nitrogen while warming to 25-30 °C. A 1.0 M solution of potassium tert-butoxide in tert-butanol (1.05 eq., 2.897 L, 2.897 mol) was added over 2 hours, maintaining the reaction temperature between 30 and 32 °C. The reaction mixture was stirred at 27-28 °C for 90 minutes. When TLC showed the reaction to be complete, ice-cold water (6 L) was added and the resultant cloudy solution extracted with EtOAc (1 x 3 L, 2 x 1.5 L). The combined organic layers were washed with brine (2 x 3 L), dried over MgSO<sub>4</sub> and evaporated *in vacuo* to give a light brown oil (441 g, 84% yield), which was used in the next stage without further purification; MW 191.23; C<sub>11</sub>H<sub>13</sub>NO<sub>2</sub>; R<sub>f</sub> 0.52 (80% EtOAc, 20% hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.40-7.29 (5H, m), 4.67 (2H, s), 4.28 (2H, s), 3.87 (2H, t, 5.4 Hz), 3.31 (2H, t, 5.4 Hz); LCMS: m/z 192 [M+H]<sup>+</sup> @ Rt 1.00 min (single major peak).

(ii) (2*R*)-4-benzyl-2-[(*S*)-hydroxy(phenyl)methyl]morpholin-3-one, (2*S*)-4-benzyl-2-[(*R*)-hydroxy(phenyl)methyl]morpholin-3-one and (2*R*)-4-benzyl-2-[(*R*)-hydroxy(phenyl)methyl]morpholin-3-one, (2*S*)-4-benzyl-2-[(*S*)-hydroxy(phenyl)methyl]morpholin-3-one






Debenzylation of (2R)-2-((R)-[phenyl][2-methylphenylthio]methyl)-4-benzylmorpholine and (2S)-2-((S)-[phenyl][2-methylphenylthio]methyl)-4-benzylmorpholine (210 mg, 0.54 mmol) following procedure described in EXAMPLE 1(iv) but at room temperature gave a colourless oil (180 mg) from which the first eluting enantiomer was obtained after chiral chromatography on a ChiralPak-OJ column eluant heptane/ethanol/dimethylethylamine (40/60/0.2) Rt 8.86min. This was converted to the title product hydrochloride salt and crystallised from isopropanol/methanol. NMR (CDCl<sub>3</sub>) 10.06 (2H, br. s), 7.20-6.93 (9H, m), 4.35-4.27 (1H, m), 4.10-3.93 (3H, m), 3.22-3.11 (2H, m), 3.03-2.86 (2H, m), 2.28 (3H, s).

### EXAMPLE 8

**(2R)-2-((R)-[phenyl][2-trifluoromethylphenylthio]methyl)morpholine hydrochloride**



#### Method 1

(i) 4-Benzylmorpholin-3-one

-27-

heptane/ethanol/dimethylethylamine (85/15/0.2) Rt 7.55min. NMR (DMSO) 9.34 (2H, br. s), 7.31-7.00 (9H, m), 4.68 (1H, d), 4.09-3.90 (1H, m), 3.98-3.87 (1H, m), 3.69-3.58 (1H, m), 3.10-3.01 (1H, m), 2.90-2.79 (3H, m). Converted to the title product hydrochloride salt.


5

# EXAMPLE 7

## (2R)-2-((R)-[phenyl][2-methylphenylthio]methyl)morpholine hydrochloride

- i) (2R)-2-((R)-[phenyl][2-methylphenylthio]methyl)-4-benzylmorpholine and (2S)-2-((S)-[phenyl][2-methylphenylthio]methyl)-4-benzylmorpholine

10



- The product was prepared as an oil (0.22g) from (R)-[phenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[phenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate (0.49g, 1.46mmol), 2-methylbenzenethiol (0.22g, 1.75mmol) and potassium carbonate (0.24g, 1.75mmol) following the procedure described in EXAMPLE 6(ii)


15

- ii) (2R)-2-((R)-[phenyl][2-methylphenylthio]methyl)morpholine hydrochloride

20


BEST AVAILABLE COPY

-26-



To a stirred suspension of (R)-[phenyl][(2S)-4-benzylmorpholin-2-yl]methyl  
methanesulphonate and (S)-[phenyl][(2R)-4-benzylmorpholin-2-yl]methyl  
methanesulphonate (790mg, 2.19mmol) and anhydrous potassium carbonate (1.50g,  
5 10.95mmol) in dry degassed DMF (3ml) under nitrogen at room temperature was added  
2-chlorobenzenethiol (1.58g, 10.95mmol). After stirring at room temperature for 18h,  
diluted with water and extracted with dichloromethane (2x). The extracts were washed  
with 2N NaOH, water and brine, dried over magnesium sulphate, filtered and evaporated  
to an oil. After purification by flash column chromatography (eluent: heptane/ethyl  
10 acetate 100/0 to 70/30 [v/v]) the product was obtained as a colourless oil (0.26g)

iii) (2R)-2-((R)-[phenyl][2-chlorophenylthio]methyl)morpholine hydrochloride



15 Debenzylation of (2R)-2-((R)-[phenyl][2-chlorophenylthio]methyl)-4-  
benzylmorpholine and (2S)-2-((S)-[phenyl][2-chlorophenylthio]methyl)-4-  
benzylmorpholine (250 mg, 0.61 mmol) following procedure described in EXAMPLE  
1(iv) but at room temperature gave a colourless oil (190 mg) from which the first eluting  
enantiomer was obtained after chiral chromatography on a ChiralPak-AD column eluant


-25-

the hydrochloride salt (36mg). NMR (DMSO) 9.20 (2H, br. s), 7.24-7.08 (6H, m), 6.92 (1H, d), 6.89 (1H, t), 4.60 (1H, d), 4.09-3.97 (2H, m), 3.80 (3H, s), 3.78-3.66 (1H, m), 3.20-3.13 (1H, m), 3.04-2.90 (3H, m), 2.24 (3H, s).

# 5 **EXAMPLE 6**

## **(2R)-2-((R)-[phenyl][2-chlorophenylthio)methyl)morpholine hydrochloride**

- i) *(R)-[Phenyl][[(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[Phenyl][[(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate*



10

To a stirred solution of (R)-[phenyl][[(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[phenyl][[(2R)-4-benzylmorpholin-2-yl]methanol (2.0g, 7.06mmol) in dry dichloromethane (24ml) at room temperature under nitrogen was added triethylamine (0.78g, 7.77mmol) and methanesulphonyl chloride (0.89g, 7.77mmol). After stirring overnight at room temperature, the reaction mixture was diluted with diethyl ether and filtered. The filtrate was evaporated to dryness to give an orange oil (2.5g).


15

- ii) *(2R)-2-((R)-[phenyl][[2-chlorophenyl]thio)methyl)-4-benzylmorpholine and (2S)-2-((S)-[phenyl][[2-chlorophenyl]thio)methyl)-4-benzylmorpholine*

20


BEST AVAILABLE COPY

-24-



Reacted (2R)-2-[(S)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine (340mg, 0.94mmol), 2-methoxybenzenethiol (161mg, 1.13mmol) and anhydrous potassium carbonate (160mg, 1.13mmol) following procedure described in example 2(iv). The crude oil was purified by flash chromatography on silica eluting with ethyl acetate/heptane 20/80 to give the product as an oil (0.21g).


v) (2R)-2-((R)-[4-methylphenyl]thio)-4-benzylmorpholine hydrochloride



Debenzylation of (2R)-2-((R)-[4-methylphenyl]thio)-4-benzylmorpholine and (2S)-2-((S)-[4-methylphenyl]thio)-4-benzylmorpholine (210 mg, 0.50 mmol) following procedure described in EXAMPLE 1(iv) but at room temperature gave a colourless oil (180 mg) from which the first eluting enantiomer was obtained after chiral chromatography on a Chiralcel-OD column, elutuant heptane/isopropanol/dimethylethylamine (20/80/0.2) Rt 9.70min. The oil was dissolved in dichloromethane and HCl/diethyl ether added to give the title compound as

-23-

iii) (2R)-2-[(S)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(4-methylphenyl)methyl]-4-benzylmorpholine



To a stirred solution of (S)-[4-methylphenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (R)-[4-methylphenyl][(2R)-4-benzylmorpholin-2-yl]methanol (1.16g, 3.91mmol) and triphenylphosphine (1.54g, 5.87mmol) in dry dichloromethane was added dropwise a solution of carbon tetrabromide (1.95g, 5.87mmol) in dichloromethane over a period of 10min. Further triphenylphosphine (0.5eq) and carbon tetrabromide (0.5eq) were added after 0.5h. Quenched reaction mixture after 2h with saturated aqueous sodium bicarbonate. Extracted with dichloromethane, dried extracts over magnesium sulphate, filtered and evaporated to a red oil. Triturated oil with diethyl ether, filtered and evaporated to a yellow oily solid. The oil was purified by flash chromatography on silica eluting with ethyl acetate/heptane 20/80 to give the product as an oil (0.61g)


iv) (2R)-2-((R)-[4-methylphenyl]thio)methyl-4-benzylmorpholine and (2S)-2-((S)-[4-methylphenyl]thio)methyl-4-benzylmorpholine

BEST AVAILABLE COPY

-22-

To a stirred solution of (+/-)-4-benzylmorpholin-3-one (4.06 g, 21.3 mmol) in anhydrous THF (25 ml) under nitrogen at -80°C was added lithium diisopropylamide (2.0M, 19.5 ml) solution in heptane/THF/ethylbenzene dropwise, whilst maintaining the reaction temperature below -65°C. The resulting solution was stirred for a further 30 minutes at -78°C, before being slowly added over approximately 45 minutes to a solution of 4-methylbenzaldehyde (3.07g, 25.51 mmol) in anhydrous THF (15 ml) under nitrogen at -78°C, whilst again maintaining the reaction temperature below -75°C. The resulting yellow solution was stirred at -78°C for 0.5 hour, before being allowed to warm to room temperature. The reaction mixture was cautiously quenched by addition of saturated ammonium chloride solution (50 ml) and the THF was evaporated *in vacuo* from the mixture. The resulting cloudy aqueous solution was extracted with dichloromethane, and the organic extracts were combined, washed with brine, dried over magnesium sulphate, filtered and the dichloromethane evaporated *in vacuo* to give a thick red oil (9.35 g). After purification by flash column chromatography (eluent: ethyl acetate/hexane 30/70 to 70/30 gradient [v/v]) the colourless oil obtained was triturated with hexane followed by hot cyclohexane to give after successive decanting of supernatant and drying the product as a colourless solid (2.46g).

ii) *(S)*-[4-methylphenyl][(2*S*)-4-benzylmorpholin-2-yl]methanol and *(R)*-[4-methylphenyl][(2*R*)-4-benzylmorpholin-2-yl]methanol




The product was prepared from (2*R*)-2-[(*S*)-(4-methylphenyl)(hydroxymethyl)-4-benzylmorpholin-3-one and (2*S*)-2-[(*R*)-(4-methylphenyl)(hydroxymethyl)-4-benzylmorpholin-3-one (2.50g, 8.04mmol) following the procedure described in EXAMPLE 2(ii). The oil was purified by flash chromatography on silica eluting with ethyl acetate/heptane gradient 30/70 to 70/30 to give required product as an oil (1.16g).



-21-

ii) (2R)-2-((R)-[2,6-dichlorophenyl][phenylthio]methyl)morpholine hydrochloride




Stirred (2R)-2-((R)-[2,6-dichlorophenyl][phenylthio]methyl)-4-benzylmorpholine  
 5 (230mg, 0.52mmol) with solid supported Hunig's base (270mg, 1.04mmol) and  $\alpha$ -  
 chloroethyl chloroformate (152mg, 1.04mmol) in dichloromethane (4ml) at room  
 temperature under nitrogen for 3h. Filtered and concentrated *in vacuo*, dissolved oil in  
 methanol and stirred at room temperature for 1h. Evaporated to give a colourless solid.  
 NMR (MeOH) 7.32-7.12 (8H, m), 4.62 (1H, d), 4.31-4.22 (1H, m), 4.16-4.06 (1H, m),  
 10 3.91-3.80 (1H, m), 3.2-2.9 (4H, m).

#### EXAMPLE 5

(2R)-2-((R)-[4-methylphenyl][2-methoxyphenyl]thio)methyl)morpholine  
hydrochloride

15 i) (2R)-2-[(S)-(4-methylphenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and  
 (2S)-2-[(R)-(4-methylphenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one




-20-

reaction mixture was purified directly by SCX chromatography eluting with ammonia/methanol (ca.3M) to give the product as an oil (174mg).

ii) (2R)-2-((R)-[2,5-dichlorophenyl][phenylthio]methyl)morpholine

5 hydrochloride



Debenzylation of (2R)-2-((R)-[2,5-dichlorophenyl][phenylthio]methyl)-4-benzylmorpholine (174mg, 0.39mmol) with polymer supported Hunig's base (0.20g, 0.78mmol) and  $\alpha$ -chloroethyl chloroformate (111mg, 0.78mmol) following the procedure described in example 1(iv) gave after SCX chromatography the product as an oil (136mg).

NMR (CDCl<sub>3</sub>) 7.31-7.14 (7H, m), 7.00 (1H, d), 4.41 (1H, d), 4.06-3.98 (1H, m), 3.90-3.82 (1H, m), 3.7-3.6 (1H, m), 2.94-2.76 (2H, m), 2.65 (2H, d).  $m/z$  [M+H] 354/6/8.

Crystallised as the HCl salt from ethanol and diethyl ether.

15

#### EXAMPLE 4

#### (2R)-2-((R)-[2,6-dichlorophenyl][phenylthio]methyl)morpholine hydrochloride

i) (2R)-2-((R)-[2,6-dichlorophenyl][phenylthio]methyl)-4-benzylmorpholine

20


Reacted (2R)-2-[(S)-bromo(phenyl)methyl]-4-benzylmorpholine (200mg, 0.58mmol) (see example 8(iv) ), 2,6-dichlorobenzenethiol (130mg, 0.70mmol) and anhydrous potassium carbonate (97mg, 0.70mmol) following example 2(iv). The reaction mixture was purified directly by SCX chromatography eluting with ammonia/methanol (ca.3M) to give the product as an oil (230mg).

25

-19-

$C_{25}H_{26}FNO_2S$ ;  $^1H$  NMR ( $CDCl_3$ ): 6.65-7.5 (13H, m), 4.9 (1H, d, 7 Hz), 3.9-4.05 (2H, m), 3.8 (3H, s), 3.6 (1H, dt, 8 Hz and 1 Hz), 3.45 (1H, d, 13.1 Hz), 3.15 (1H, d, 13.1 Hz), 2.60 (2H, t, 8 Hz), 2.05-2.2 (2H, m); FIA:  $m/z$  424  $[M+H]^+$ .

- 5 v) (2R)-2-((R)-(2-Fluorophenyl)[[2-methoxyphenyl]thio)methyl)morpholine hydrochloride



- Reaction of the mixture of (2R)-2-((R)-[2-fluorophenyl][[2-methoxyphenyl]thio)methyl)-4-benzylmorpholine and (2S)-2-((S)-[2-fluorophenyl][[2-methoxyphenyl]thio)methyl)-4-benzylmorpholine (430 mg, 1.02 mmol) following  
 10 procedure described in EXAMPLE 1(iv) gave a colourless oil (340 mg, 90% yield) from which the first eluting enantiomer was obtained after chiral chromatography on a Chiralcel-OD column eluant heptane/ethanol/dimethylethylamine (40/60/0.2):  $R_t$  10.41 min. LC purity = 98.6 ( $UV_{254nm}$ ); MW 333.43;  $C_{18}H_{20}FNOS$ .; FIA:  $m/z$  334  $[M+H]^+$ . This  
 15 was converted into the hydrochloride salt.  $^1H$  NMR ( $CDCl_3$ ) freebase: 7.2-7.3 (1H, m), 6.85-7.2 (8H, m), 4.85 (1H, d, 8 Hz), 3.95-4.15 (2H, m), 3.85-3.9 (3H, m), 3.7 (1H, dt, 1 Hz and 7 Hz), 2.6-3.0 (4H, m).

### EXAMPLE 3


- 20 (2R)-2-((R)-[2,5-dichlorophenyl][phenylthio)methyl)morpholine hydrochloride

- i) (2R)-2-((R)-[2,5-dichlorophenyl][phenylthio)methyl)-4-benzylmorpholine

- Reacted (2R)-2-[(S)-bromo(phenyl)methyl]-4-benzylmorpholine (150mg, 0.43mmol) (see example 8(v)method 2), 2,5-dichlorobenzenethiol (233mg, 1.30mmol)  
 25 and anhydrous potassium carbonate (71mg, 0.52mmol) following example 2(iv). The


BEST AVAILABLE COPY

-18-



To a stirred solution of (R)-[2-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[2-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol (465mg, 1.54mmol) in dry dichloromethane (10ml) at room temperature under nitrogen was added triethylamine (202mg, 2.0mmol) and methanesulphonyl chloride (177mg, 1.54mmol). After 15h, evaporated to an oil and purified by flash chromatography on silica eluting with ethyl acetate/heptane (1/1) to give the product mesylate as a colourless oil (445mg).

- iv) (2R)-2-((R)-[2-fluorophenyl][[2-methoxyphenyl]thio)methyl)-4-benzylmorpholine and (2S)-2-((S)-[2-fluorophenyl][[2-methoxyphenyl]thio)methyl)-4-benzylmorpholine




To a stirred suspension of (R)-[2-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[2-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate (445mg, 1.17mmol) and anhydrous potassium carbonate (0.97g, 7.02mmol) in dry degassed DMF (8ml) under nitrogen at room temperature was added 2-methoxybenzenethiol (0.82g, 5.87mmol). After stirring at room temperature for 18h, diluted with water and extracted with diethyl ether (2x). The extracts were washed with 2NaOH, water and brine, dried over magnesium sulphate, filtered and evaporated to an oil.

After purification by flash column chromatography (eluent: heptane/ethyl acetate 80/20 [v/v]) the title product was obtained as a colourless oil (357 mg); MW 423.55;

-17-

ii) (R)-[2-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[2-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol



5 To a stirred solution of (2R)-2-[(R)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one, (2S)-2-[(S)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one, (2R)-2-[(S)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(R)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one (12.0g, 0.038mol) in dry THF (80ml) under nitrogen at room  
10 temperature was added a solution of borane in THF (1M, 150ml). The solution was heated at 60°C for ca. 4h then at room temperature overnight. Cooled solution to 0°C and added dropwise methanol (68ml) followed by 1NHCl (68ml). The resulting mixture was heated at 60°C for 1h, cooled and concentrated *in vacuo*. The precipitate was removed by  
15 filtration and the filtrate made basic with aqueous sodium carbonate. Extracted with diethyl ether (3x), extracts washed with water and brine, dried over magnesium sulphate, filtered and evaporated to an oil. The crude oil was purified and partially separated by flash chromatography on silica eluting with heptane/ethyl acetate (40/60 to 25/75) to give the product as a colourless oil (0.713g).

20 iii) (R)-[2-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[2-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate

25


-16-

a colourless oil. The desired diastereomer was separated on chiralcel-OJ column eluting with heptane/ethanol/dimethylethylamine (20/80/0.2) : 8.98 min. The required product was then obtained (60%de) after chiral chromatography on chirapak-OD column eluting with heptane/isopropanol (70/30) : 17.41min. It was converted into the HCl salt, NMR (DMSO) 9.39 (2H, br. s), 7.3-7.1 (4H, m), 6.94-6.72 (4H, m), 4.6-4.5 (1H, m), 4.12-3.92 (2H, m), 3.85-3.62 (7H, m), 3.46-3.32 (1H, m), 3.20-3.08 (1H, m), 3.04-2.89 (2H, m). LCMS:  $m/z$  346  $[M+H]^+$  @ Rt 4.24 min.

**EXAMPLE 2:**


10 **(2R)-2-((R)-(2-Fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine hydrochloride**

i) (2R)-2-[(R)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one, (2S)-2-[(S)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one, (2R)-2-[(S)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(R)-(2-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one




To a stirred solution of (+/-)-4-benzylmorpholin-3-one (10.0g, 0.052mol) and 2-fluorobenzaldehyde (7.74g, 0.062mol) in dry THF (80ml) cooled under nitrogen to  $-78^{\circ}\text{C}$  was added dropwise a solution of lithium diisopropylamide in heptane/THF/ethylbenzene (2M, 31.2ml). After addition, stirred at  $-78^{\circ}\text{C}$  for 0.5h then allowed to warm to  $0^{\circ}\text{C}$  before quenching with aqueous saturated ammonium chloride. Concentrated *in vacuo* and extracted with dichloromethane (2x). The extracts were dried over magnesium sulphate, filtered and evaporated to an oil. Purified on a pad of flash silica eluting with heptane/ethyl acetate (100/0, 80/20, 60/40 and 50/50) to give a 1:1 mixture of the diastereomers as a colourless oil (12.05g).

-15-



A mixture of (R)-[4-methoxyphenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[4-methoxyphenyl][(2R)-4-benzylmorpholin-2-yl]methanol (118mg, 0.376mmol), 2,2'-dimethoxydiphenyldisulphide (210mg, 0.75mmol) and tributylphosphine (152mg, 1.50mmol) in dry THF (2ml) was heated at reflux under nitrogen overnight. The reaction mixture was cooled to room temperature and evaporated to an oil. The crude oil was purified by flash chromatography on silica eluting with heptane/ethyl acetate (4/1 then 3/2) to give the product as a colourless oil (95mg).

iv) (2R)-2-((R)-[4-methoxyphenyl]{{[2-methoxyphenyl]thio}methyl)morpholine hydrochloride




Stirred (2S)-2-((S)-[4-methoxyphenyl]{{[2-methoxyphenyl]thio}methyl)-4-benzylmorpholine (2R)-2-((R)-[4-methoxyphenyl]{{[2-methoxyphenyl]thio}methyl)-4-benzylmorpholine (618mg, 1.42mmol) with solid supported Hunig's base (2.40g, 8.52mmol) and  $\alpha$ -chloroethyl chloroformate (2.0g, 14.21mmol) in dichloromethane (12ml) at room temperature under nitrogen for 4h. Filtered and concentrated *in vacuo*, dissolved oil in methanol and heated at 60°C for 1.5h. Cooled to room temperature and purified by SCX column chromatography eluting with ammonia/methanol (ca. 3M) gave

BEST AVAILABLE COPY

-14-

HCl (25ml) dropwise. After 5 min. stirring, made basic by addition of 2M NaOH and the resulting suspension filtered through celite. The aqueous phase was separated and washed with diethyl ether (2x). The combined organic phases was dried over magnesium sulphate, filtered and evaporated to a yellow oil. The oil was purified by flash chromatography on silica eluting with ethyl acetate/heptane gradient 25/75 to 70/30 to give required product as a yellow oil (5.46g).

ii) (R)-[4-methoxyphenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[4-methoxyphenyl][(2R)-4-benzylmorpholin-2-yl]methanol



10

To a stirred solution of (+/-)-[4-Methoxyphenyl][4-benzylmorpholin-2-yl]methanone (5.40g, 17.36mmol) in methanol (60ml) at 5°C was added sodium borohydride (1.31g, 34.72mmol) portionwise. The mixture was stirred at room temperature for 1.5h, cooled to 10°C and added water to terminate reaction. Concentrated in vacuo, diluted with water and extracted with ethyl acetate (2x). Extracts washed with water and brine, dried over magnesium sulphate, filtered and evaporated to an oil. The crude mixture of diastereomers was purified and separated by flash chromatography on silica eluting with diethyl ether/toluene (3/2) to give the title diastereomer as a colourless oil (2.14g).

20

iii) (2R)-2-((R)-[4-methoxyphenyl][2-methoxyphenylthio]methyl)-4-benzylmorpholine and (2S)-2-((S)-[4-methoxyphenyl][2-methoxyphenylthio]methyl)-4-benzylmorpholine




-13-

Stereochemical Conventions

The absolute stereochemistry of compounds according to the present invention may be determined by reference to X-ray crystallography for the following (2S,2'S)

5 compound



X-ray crystallographic data for the above compound is listed in Tables 1-6 herein.


All of the Examples herein were obtained as single isomers either through the use of chirally pure starting material or chiral separation methods, such as HPLC.

10

EXAMPLE 1

(2R)-2-((R)-[4-methoxyphenyl][2-methoxyphenylthio)methyl)morpholine  
hydrochloride

15 i) (+/-)-[4-Methoxyphenyl][(4-benzylmorpholin-2-yl)methanone



To stirred magnesium turnings (5.4g, 0.22mol) in dry THF (20ml) at room temperature under nitrogen was added sufficient 1,2-dibromoethane (ca. 0.3ml) to create an exotherm. A solution of 4-bromoanisole (13.90g, 74.25mmol) in dry THF (25ml) was then added dropwise at a rate to maintain a gentle reflux. After addition, allowed to cool to below 30°C then added over 5 min. period to a stirred solution of 4-benzyl-2-cyanomorpholine (5.0g, 24.75mmol) in dry THF (50ml) cooled to -20°C under nitrogen. After addition stirred at room temperature for 30 min. then cooled to 0°C and added 5M

20

-12-

carrier or diluted by a carrier, and/or enclosed within a carrier which may, for example, be in the form of a capsule, sachet, paper or other container. Where the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition may be in the form of tablets, 5 lozenges, sachets, cachets, elixirs, suspensions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.

Some examples of suitable carriers are lactose, dextrose, vegetable oils, benzyl 10 alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as starch and petroleum jelly, sucrose sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl- hydrobenzoate, talc, magnesium stearate and mineral oil. The compounds of formula (I) can also be lyophilized and the lyophilizates obtained used, for 15 example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins. Compositions of the invention may be formulated so as to provide, 20 quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage unit containing from about 5 to about 500 mg, more usually about 25 to about 300 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units 25 suitable as unitary doses for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.

The following Examples illustrate compounds of the present invention and 30 methods for their synthesis.

urinary incontinence or persistent pain, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The present invention includes the pharmaceutically acceptable salts of the compounds of formula I and formula II. Suitable salts include acid addition salts, including salts formed with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic or organic sulphonc acids, for example, acetoxybenzoic, citric, glycolic, *o*- mandelic-l, mandelic-dl, mandelic d, maleic, mesotartaric monohydrate, hydroxymaleic, fumaric, lactobionic, malic, methanesulphonic, napsylic, naphthalenedisulfonic, naphtoic, oxalic, palmitic, phenylacetic, propionic, pyridyl hydroxy pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, 2-hydroxyethane sulphonc, toluene-p-sulphonc, and xinafoic acids.

In addition to the pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically acceptable, acid addition salts, or are useful for identification, characterisation or purification.

It will be appreciated that compounds of formula I and formula II possess one or more asymmetric carbon atoms, and that the present invention is directed specifically to individual stereoisomers. The particular stereochemistry of the present compounds is essential to the pharmacological profile of the compounds. In the present specification, where a structural formula does not specify the stereochemistry at one or more chiral centres, it encompasses all possible stereoisomers and all possible mixtures of stereoisomers (including, but not limited to, racemic mixtures), which may result from stereoisomerism at each of the one or more chiral centers.

The compounds of the present invention may be used as medicaments in human or veterinary medicine. The compounds may be administered by various routes, for example, by oral or rectal routes, topically or parenterally, for example by injection, and are usually employed in the form of a pharmaceutical composition.

Such compositions may be prepared by methods well known in the pharmaceutical art and normally comprise at least one active compound in association with a pharmaceutically acceptable diluent, excipient or carrier. In making the compositions of the present invention, the active ingredient will usually be mixed with a

BEST AVAILABLE COPY

-10-

formula I or a pharmaceutically acceptable salt thereof, for use as a selective inhibitor of the reuptake of both serotonin and norepinephrine. Preferably such selective inhibition occurs within mammalian cells (including mammalian cell membrane preparations), especially those found within the central and/or peripheral nervous system. More preferably such selective inhibition occurs within the cells of the central nervous system of a mammal, especially a human, in need thereof.

The present invention also provides the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for selectively inhibiting the reuptake of serotonin and norepinephrine; the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders associated with serotonin and norepinephrine dysfunction in mammals; the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain; and the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder selected from depression, stress urinary incontinence, and persistent pain. The present invention further provides a compound of formula I or formula II for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, for example a disorder selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain, especially depression, stress urinary incontinence, and persistent pain.

Further the present invention provides a method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or formula II or a pharmaceutically acceptable salt thereof; a method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or formula II or a pharmaceutically acceptable salt thereof; and a method for treating a disorder selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain, especially depression, stress

BEST AVAILABLE COPY

For clinical purposes, pain may be divided into two categories: acute pain and persistent pain. Acute pain is provoked by noxious stimulation produced by injury and/or disease of skin, deep somatic structures or viscera, or abnormal function of muscle or viscera that does not produce actual tissue damage. On the other hand, persistent pain can be defined as pain that persists beyond the usual course of an acute disease or a reasonable time for an injury to heal or that is associated with a chronic pathologic process that causes continuous pain or the pain recurs at intervals for months or years. If pain is still present after a cure should have been achieved, it is considered persistent pain. For the purpose of the present invention, persistent pain can be chronic non-remitting or recurrent. The difference in definition between acute and persistent pain is not merely semantic but has an important clinical relevance. For example, a simple fracture of the wrist usually remains painful for a week to 10 days. If the pain is still present beyond the typical course of treatment, it is likely that the patient is developing reflex sympathetic dystrophy, a persistent pain syndrome that requires immediate effective therapy. Early and effective intervention potentially prevents the undue disability and suffering, and avoids the potential development of a condition that becomes refractory to therapy.

Acute and chronic pain differ in etiology, mechanisms, pathophysiology, symptomatology, diagnosis, therapy, and physiological responses. In contrast to the transitory nature of acute pain, persistent pain is caused by chronic pathologic processes in somatic structures or viscera, by prolonged and sometimes permanent dysfunction of the peripheral or central nervous system, or both. Also, persistent pain can sometimes be attributed to psychologic mechanisms and/or environmental factors.


Current therapies for persistent pain include opiates, barbiturate-like drugs such as thiopental sodium and surgical procedures such as neurectomy, rhizotomy, cordotomy, and corpectomy.

References herein to pain are intended to refer to persistent pain.

The present invention provides pharmaceutical compositions comprising a compound of formula I or formula II or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

Further, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical; and a compound of

-8-




Scheme 4

Compounds of the present invention are selective inhibitors of the reuptake of both serotonin and norepinephrine and as such are useful as pharmaceuticals. They may be indicated in the treatment of disorders associated with serotonin and norepinephrine dysfunction in mammals, including depression, eating disorders (including bulimia and anorexia nervosa), inflammatory bowel disorders, functional bowel disorders, dyspepsia, chron's disease, ileitis, ischemic bowel disease, ulcerative colitis, gastroesophageal reflux for functional bowel disorders, irritable bowel syndrome, obesity, interstitial cystitis, urethral syndrome, gastric motility disorders, substance abuse (including alcoholism, tobacco abuse, symptoms caused by withdrawal or partial withdrawal from the use of tobacco or nicotine and drug addiction including cocaine abuse) , smoking cessation, pain (including inflammatory pain, neuropathic pain, non-neuropathic non-inflammatory pain, persistent pain, persistent pain of inflammatory and/or neuropathic origin, headache and migraine), urinary incontinence (including stress urinary incontinence and urge incontinence), dementia of ageing, senile dementia, Alzheimer's, memory loss, Parkinsonism, attention-deficit disorder (including attention-deficit hyperactivity disorder), anxiety, social phobia, disruptive behavior disorders, conduct disorders, impulsive control disorders, borderline personality disorder, chronic fatigue syndrome, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder, schizophrenia, gastrointestinal disorders, cardiovascular disorders, emesis, sleep disorders, cognitive disorders, psychotic disorders, brain trauma, premenstrual syndrome or late luteal syndrome, sexual dysfunction (including premature ejaculation and erectile difficulty), autism, mutism and trichotilomania. The compounds of the present invention are particularly suitable for the treatment of pain.

chloroethyl chloroformate as described in the specific examples. Deprotection may also be achieved by reaction with phenylchloroformate followed by quenching of the generated benzyl chloride with dimethylamine prior to isolation of the phenylcarbamate intermediate which is then hydrolysed in isopropanol in the presence of 30% NaOH.

5 Detail of route B is given in Scheme 3:




Scheme 3

Treatment of *N*-benzyl morpholinone with a strong base such as lithium diisopropylamide at low temperature followed by addition of benzaldehyde gives aldol adducts as a 2:1 mixture of diastereomer pairs, which may be separated using conventional chromatographic techniques. Reduction with a borane reagent at elevated temperatures gives diastereomeric amino alcohol pairs.

Amino alcohol pair (2*S*,2'*S*) and (2*R*,2'*R*) may be converted to bromide and further to racemic aryl thio morpholines as outlined in Scheme 4. Amino alcohol pair (2*R*,2'*S*) and (2*S*,2'*R*) may be converted into the corresponding mesylate. Displacement with the requisite thiol, followed by removal of the nitrogen protecting group furnishes aryl thiol morpholines as racemic mixtures of two diastereomers. The racemic aryl thiol morpholines may be separated into enantiomerically pure products using chiral HPLC technology.


-6-

phenyl and R' and R<sup>1</sup> are shown as H. It will be appreciated that analogous methods could be applied for other possible identities of X, R' and R<sup>1</sup>.



Scheme 1

5 More detail of Route A is given in Scheme 2:




Scheme 2

The amino alcohol can be obtained by reaction of N-benzyl-cyanomorpholine with a Grignard reagent, followed by acid hydrolysis to give racemic phenyl ketone which may be separated on chiral HPLC. (2R)-Phenyl ketone may then be reduced with DIP-Cl to give the amino alcohol in high diastereomeric excess. The amino alcohol may be converted into the benzyl bromide to give the desired N-substituted aryl thio morpholines after displacement with the requisite aryl thiol. Deprotection of the tertiary amine gives the final products. Deprotection may be achieved by reaction with  $\alpha$ -




-5-



(III)

where R<sub>5</sub> is a protecting group, e.g. benzyl, X, R' and R<sup>1</sup> are as formula I above and Y is a leaving group, with an aryl thiol. Examples of suitable leaving groups include halo and mesylate, but the nature of the leaving group is not critical.

Compounds of the present invention may also be prepared by deprotecting a compound of the formula (IV):



(IV)

where R<sub>5</sub> is a protecting group, e.g. benzyl, and Ar, X, R' and R<sup>1</sup> are as defined in formula (I) above to provide a compound of formula (I), optionally followed by the step of forming a pharmaceutically acceptable salt.

Suitable N-protecting groups will be known to the person skilled in the art as will methods for their removal. Further information on suitable deprotecting groups is contained in the well known text "Protective Groups in Organic Synthesis", Theodora W. Greene and Peter G.M. Wuts, John Wiley & Sons, Inc., New York, 1999, pp.494-653. Preferred N-protecting groups include benzyl, allyl, carbamates such as benzyloxycarbonyl (cbz) and t-butyloxycarbonyl (boc) and amides.

Compounds of the present invention may be prepared by conventional organic chemistry techniques from N-benzyl-cyanomorpholine 1 (Route A) or N-benzyl-morpholinone 2 (Route B) as outlined in Scheme 1 below. For clarity, X is shown as

BEST AVAILABLE COPY

salts exhibit a  $K_i$  value less than 50nM at the norepinephrine transporter and a  $K_i$  value less than 50nM at the serotonin transporter. Especially preferred compounds of Formula (I) and their pharmaceutically acceptable salts exhibit a  $K_i$  value less than 20nM at the norepinephrine transporter and a  $K_i$  value less than 20nM at the serotonin transporter.

5 Preferably, compounds of the present invention selectively inhibit the norepinephrine and serotonin transporters relative to the dopamine transporter by a factor of at least five, more preferably by a factor of at least ten. Advantageously, they have a reduced interaction (both as substrate and inhibitor) with the liver enzyme Cytochrome P450 (CYP2D6). That is to say, they preferably exhibit less than 75% metabolism via the  
10 CYP2D6 pathway according to the CYP2D6 substrate assay described below and they preferably exhibit an  $IC_{50}$  of  $>6\mu M$  according to the CYP2D6 inhibitor assay described below. They are particularly useful for the treatment of disorders associated with serotonin and norepinephrine dysfunction in mammals, such as CNS disorders including depression, persistent pain and stress urinary incontinence.

15 The term "serotonin and norepinephrine dysfunction" as used herein refers to a reduction in the amount of serotonin and norepinephrine neurotransmitter within the synaptic cleft below that which would be considered to be normal. Thus the phrase "disorders associated with serotonin and norepinephrine dysfunction in mammals" refers to disorders which are associated with a reduction in the amount of serotonin and  
20 norepinephrine neurotransmitter within the synaptic cleft below that which would be considered to be normal for the mammalian species in question. Some examples of disorders currently believed to be associated with reduced levels of serotonin and norepinephrine within the synaptic cleft are detailed below.

The compounds of the present invention are also indicated for the treatment of  
25 disorders which are ameliorated by an increase in the amount of serotonin and norepinephrine neurotransmitter within the synaptic cleft of a mammal above that which would be considered to be normal for the mammalian species in question.

The term "treatment" as used herein refers to both curative and prophylactic treatment of disorders associated with serotonin and norepinephrine dysfunction.

30 Compounds of the present invention may be prepared by reacting a compound of the formula (III):


For the compounds of formula (I) above, R' is preferably H or Me. More preferably R' is H.

For the compounds of formula (I) above, each R<sup>1</sup> is preferably H or Me with 0, 1, 2 or 3 of R<sup>1</sup> being Me. More preferably only 1 R<sup>1</sup> is Me. Most preferably all R<sup>1</sup> are H.

5 For the compounds of formula (I) above, it is preferred that R' and all R<sup>1</sup> are H.

Particularly preferred substituents for the Ar group include trifluoromethyl and methoxy.

A preferred group of compounds according to the present invention is represented by formula (II);



(II)

in which R<sub>2</sub> and R<sub>3</sub> are each independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, and phenyl; and

R<sub>4</sub> is selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, and O(C<sub>1</sub>-C<sub>4</sub> alkyl) and halo; and pharmaceutically acceptable salts thereof.


R<sub>2</sub> is preferably C<sub>1</sub>-C<sub>2</sub> alkyl, O(C<sub>1</sub>-C<sub>2</sub> alkyl), S(C<sub>1</sub>-C<sub>2</sub> alkyl), Cl or F. R<sub>3</sub> is preferably H, Me or Cl. R<sub>4</sub> is preferably H, C<sub>1</sub>-C<sub>2</sub> alkyl, O(C<sub>1</sub>-C<sub>2</sub> alkyl), Cl or F.

The compounds of the present invention are dual reuptake inhibitors of serotonin and norepinephrine. Biogenic amine transporters control the amount of biogenic amine neurotransmitters in the synaptic cleft. Inhibition of the respective transporter leads to a rise in the concentration of that neurotransmitter within the synaptic cleft. Compounds of Formula (I) and their pharmaceutically acceptable salts preferably exhibit a K<sub>i</sub> value less than 100nM at the norepinephrine transporter and a K<sub>i</sub> value less than 100nM at the serotonin transporter as determined using the scintillation proximity assays as described below. More preferred compounds of Formula (I) and their pharmaceutically acceptable

BEST AVAILABLE COPY

-2-

According to the present invention there is provided a compound of formula (I)



wherein

5 R is H;

Ar is an aromatic group selected from phenyl; X is a phenyl group; R' is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and each R<sub>1</sub> is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl; and pharmaceutically acceptable salts thereof.

10 The aromatic group Ar may be substituted or unsubstituted phenyl. For example, Ar may be unsubstituted phenyl or, preferably, phenyl substituted with 1, 2, 3, 4 or 5 substituents, preferably with 1 or 2, for example 1, substituent. The substituted phenyl group is preferably substituted in the 2-position. Suitable substituents include C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, and phenyl, optionally substituted with, for example, halo, C<sub>1</sub>-C<sub>4</sub> alkyl or O(C<sub>1</sub>-C<sub>4</sub> alkyl).


15 The group X may be substituted or unsubstituted phenyl. For example, X may be phenyl substituted with 1, 2, 3, 4 or 5 substituents, preferably with 1 substituent. Suitable substituents include C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), and halo.

20 "C<sub>1</sub>-C<sub>4</sub> alkyl" as used herein includes straight and branched chain alkyl groups of 1, 2, 3 or 4 carbon atoms, and may be unsubstituted or substituted. C<sub>1</sub>-C<sub>2</sub> alkyl groups are preferred. Suitable substituents include halo. Thus the term "C<sub>1</sub>-C<sub>4</sub> alkyl" includes haloalkyl. Similar terms defining different numbers of C atoms (e.g. "C<sub>1</sub>-C<sub>2</sub> alkyl") take an analogous meaning. When R' is C<sub>1</sub>-C<sub>4</sub> alkyl it is preferably unsubstituted. When R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl it is preferably unsubstituted.

"Halo" includes F, Cl, Br and I, and is preferably F or Cl.

-52-


iv)



Cesium carbonate (546mg, 1.68mmol) was added to a stirred solution of (2R)-2-  
 5 [(S)-bromo(3-fluorophenyl)methyl]-4-benzylmorpholine and (2S)-2-[(R)-bromo(3-fluorophenyl)methyl]-4-benzylmorpholine (510mg, 1.4mmol) and 2-methoxybenzenethiol (235mg, 1.68mmol) in dry dimethylformamide (3ml). The suspension was stirred at room temperature for 4h. The reaction mixture was diluted with iced water, 2M aqueous sodium hydroxide (1ml) and extracted with diethyl ether (15ml).  
 10 The extracts were washed with brine solution, dried, filtered and evaporated to a yellow oil (627mg). The crude product was purified by chromatography on silica eluting with ethyl acetate:heptane 20:80 to give 2(R)-2-((R)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl-4-benzylmorpholine as a pale yellow oil (466mg, 79%)

15


v)



Alpha-chloroethyl chloroformate (0.235ml, 2.17mmol) was added to a gently stirred suspension of polystyrene supported diisopropylethylamine (Argonaut, 306mg, 20 1.09mmol) and 2(R)-2-((R)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl-4-


-53-

- benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl)-4-benzylmorpholine (460mg, 1.09mmol) in dichloromethane (6ml) at room temperature under nitrogen. After 16h, the suspension was filtered and the filtrate evaporated. The residue was dissolved in methanol (6ml) and heated to 60°C for 1h. The solution was
- 5 evaporated and the solid residue crystallised from isopropanol (15ml) and n-hexane to give a white solid (371mg, 92%). The racemic hydrochloride salt was converted to the free base by stirring in dichloromethane (20ml) and aqueous sodium hydroxide (0.5M, 20ml). The dichloromethane layer was separated, dried, filtered and evaporated to a colourless oil (341mg). Chiral preparative chromatography (Chiralcel-OD,
- 10 heptane:ethanol:dimethylethylamine 50:50:0.2) was used to isolate the first eluting enantiomer Rt 9.2min as an oil. This was redissolved in diethylether and treated with ethereal hydrogen chloride to give the title product (2R)-2-((R)-[3-fluorophenyl][2-methoxyphenyl]thio)methyl)morpholine hydrochloride as a solid (138mg, 34%, mp 233-234°C). NMR (DMSO) 9.26 (2H, br. s), 7.31 (1H, q), 7.10-7.20 (4H, m), 7.05 (1H, t),
- 15 6.92 (1H, d), 6.78 (1H, t), 4.66 (1H, d), 4.0-4.15 (2H, m), 3.77 (3H, s), 3.72 (1H, t), 3.19 (1H, d), 2.92-3.1 (3H, m). LCMS:  $m/z$  334  $[M+H]^+$  @ Rt 3.5 min

**EXAMPLE 14:****(2R)-2-((R)-[3-fluorophenyl][2-ethoxyphenyl]thio)methyl)morpholine****20 hydrochloride****Method 1**


i)

-54-



- A solution of borane in tetrahydrofuran (1M, 25.2ml) was added dropwise to a stirred solution of diastereomer 2 from example 13(i) (2R)-2-[(R)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and (2S)-2-[(S)-(3-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one (2.0g 6.3mmol) in dried tetrahydrofuran (25ml) at room temperature under nitrogen causing effervescence. The solution was heated to 60°C for 1.5h, allowed to cool to room temperature and excess borane quenched by adding methanol (10ml) slowly. Aqueous hydrochloric acid (1M, 13ml) was added, heated to 60°C for 1h and then evaporated to a white solid. Added saturated aqueous sodium carbonate (50ml) and diethyl ether (50ml) to dissolve the solid and extracted with diethyl ether (2x 50ml). The extracts were washed with brine solution, dried, filtered and evaporated to a colourless oil (2.01g). The oil was dissolved in isopropanol (20ml) and ethereal hydrogen chloride (2M, 3ml) added to crystallise the salt (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol hydrochloride and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol hydrochloride as a white solid (1.66g, 78%)

ii)




- Methanesulphonyl chloride (1.01g, 8.9mmol) was added dropwise over 5min to a stirred solution of (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol

-55-

hydrochloride and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol hydrochloride (1.50g, 4.44mmol) and triethylamine (1.79g, 17.8mmol) in dry dichloromethane (30ml) at room temperature under nitrogen atmosphere. After 1h, water (30ml) was added, stirred vigorously and then the dichloromethane layer separated. The solution was dried over sodium sulphate, filtered and evaporated to a colourless oil. The oil was purified by chromatography on silica eluting with diethyl ether:hexane 3:1 to give (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate as a colourless oil (1.51g, 90%)

10

iii)




Anhydrous potassium carbonate (276mg, 2mmol) was added to a stirred solution of (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate (682mg, 1.8mmol) and 2-ethoxybenzenethiol (308mg, 2mmol) in dry dimethylformamide (13ml) at room temperature under nitrogen atmosphere. After 3 days, water (25ml) was added and the mixture extracted with diethyl ether (25ml). The extracts were washed with brine solution (20ml), dried, filtered and evaporated to a yellow oil (0.89g). The product was purified by chromatography on silica eluting with ethyl acetate:heptane 20:80 to give 2(R)-2-((R)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)-4-benzylmorpholine as a colourless oil (493mg, 63%).

25



-56-

iv)




Debenzylation of 2(R)-2-((R)-[3-fluorophenyl][2-ethoxyphenyl]thio)methyl-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl][2-ethoxyphenyl]thio)methyl-4-benzylmorpholine (480mg, 1.1mmol) using the method described in example 13(v) gave the racemic hydrochloride salt (360mg, 85%). After conversion to the free base, chiral preparative chromatography (Chiralcel-OD, heptane:ethanol:dimethylethylamine 80:20:0.2) was used to isolate the first eluting enantiomer Rt 14.9min as an oil. This was redissolved in diethylether and treated with ethereal hydrogen chloride to give the title product (2R)-2-((R)-[3-fluorophenyl][2-ethoxyphenyl]thio)methylmorpholine hydrochloride as a solid (144mg, 34%, mp 211-215°C). NMR (DMSO) 9.30 (2H, br. s), 7.31 (1H, q), 7.11-7.20 (4H, m), 7.05 (1H, t), 6.91 (1H, d), 6.79 (1H, t), 4.64 (1H, d), 3.97-4.15 (4H, m), 3.72 (1H, t), 3.19 (1H, d), 2.92-3.1 (3H, m), 1.37 (3H, t). LCMS:  $m/z$  348  $[M+H]^+$  @ Rt 4.1 min

15

## Method 2

i)




A solution of 3-fluorophenylmagnesium bromide (0.5M, 50ml, 25mmol) was added dropwise to a stirred solution of 4-benzyl-morpholin-2-carbonitrile (4.59g, 22.7mmol) in diethyl ether (50ml) at 0°C under nitrogen. After 45min at 0°C the mixture

-57-

was allowed to warm to room temperature for 30min then recooled and quenched by the addition of aqueous hydrochloric acid (5M, 40ml) –caution exothermic. After 30min at room temperature, the acidic mixture was basified with sodium hydroxide (5M, 60ml) and extracted with ethyl acetate (3x 150ml). The combined extracts were washed with  
5 brine solution, dried, filtered and concentrated in vacuo to give (+/-)-(4-benzyl-morpholin-2-yl)-(3-fluorophenyl)methanone (6.9g) as a yellow oil.


ii)



10

Borontrifluoride etherate (27.6g, 194mmol) followed by trifluoroacetic acid (40ml) were added to a stirred solution of (+/-)-(4-benzyl-morpholin-2-yl)-(3-fluorophenyl)methanone (23.28g, 77mmol) and triphenylsilane (81.1g, 311mmol) in dichloromethane (1000ml) at 0°C under nitrogen. After 16h at room temperature, reaction  
15 mixture was cooled and carefully basified by addition of aqueous sodium bicarbonate. The organic layer was separated, dried and concentrated in vacuo. The residual orange oil was purified using SCX-2 resin to absorb the amine product. Elution with methanolic ammonia (2M) and concentration in vacuo gave an oil (30g) that was further purified by chromatography on silica (toluene:diethyl ether 60:40) to give (R)-[3-fluorophenyl][(2S)-  
20 4-benzylmorpholin-2-yl]methanol and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol as an oil (19.7g, 84%).

iii)




-58-


Conversion of (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol (19.7g) using method 1 in example 14(ii) gave (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate (24.7g) was followed by method 1 in example 14(iii) to give 2(R)-2-((R)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)-4-benzylmorpholine (22.5g). This was debenzylated by method 1 in example 14(iv) to give (2R)-2-((R)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)morpholine and (2S)-2-((S)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)morpholine (15.2g) followed by preparative chiral chromatography to separate the first eluting enantiomer (7.7g) and then salt formation to the title product (2R)-2-((R)-[3-fluorophenyl]{[2-ethoxyphenyl]thio}methyl)morpholine hydrochloride (4.38g) as a white crystalline solid.

### 15 EXAMPLE 15

(2R)-2-((R)-[3-fluorophenyl]{[2-chlorophenyl]thio}methyl)morpholine hydrochloride



i)




-59-

Anhydrous potassium carbonate (377mg, 2.73mmol) was added to a stirred solution of (R)-[3-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methyl methanesulphonate and (S)-[3-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methyl methanesulphonate (740mg, 1.8mmol) and 2-chlorobenzenethiol (393mg, 2.73mmol) in dry dimethylformamide (10ml) at room temperature under nitrogen atmosphere. After 44h, diluted with methanol (15ml) and the inorganic solid filtered. The filtrate was poured directly onto SCX-2 columns (3x 10g), washed with methanol and the basic product eluted with methanolic ammonia (2M) to give a yellow oil (707mg) after evaporation.

10 The product was further purified by chromatography on silica eluting with ethyl acetate:heptane 20:80 to give 2(R)-2-((R)-[3-fluorophenyl]{[2-chlorophenyl]thio}methyl)-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl]{[2-chlorophenyl]thio}methyl)-4-benzylmorpholine as a colourless oil (653mg, 78%).

15 ii)



Alpha-chloroethyl chloroformate (0.33ml, 3.06mmol) was added to a gently stirred suspension of polystyrene supported diisopropylethylamine (Argonaut, 429mg, 1.53mmol) and 2(R)-2-((R)-[3-fluorophenyl]{[2-chlorophenyl]thio}methyl)-4-benzylmorpholine and 2(S)-2-((S)-[3-fluorophenyl]{[2-chlorophenyl]thio}methyl)-4-benzylmorpholine (429mg, 1.53mmol) in dichloromethane (10ml) at room temperature under nitrogen. After 2h, the suspension was filtered and the filtrate evaporated. The residue was dissolved in methanol (10ml) and heated to 60°C for 1h. The solution was evaporated to the hydrochloride salt, redissolved in methanol and converted to the free

25 base using SCX-2 column (10g) eluting with methanol and then methanolic ammonia (2M) to give a colourless oil (501mg, 97%). Chiral preparative chromatography


-60-

(Chiralcel-OJ, heptane:isopropanol:dimethylethylamine 90:10:0.2) was used to isolate the first eluting enantiomer Rt 19.2min as an oil. This was redissolved in diethylether and treated with ethereal hydrogen chloride to give the title product (2R)-2-((R)-[3-fluorophenyl]{{[2-chlorophenyl]thio}methyl)morpholine hydrochloride as a solid (231mg, 5 40%, mp 183-7°C). NMR (DMSO) 9.38 (2H, br. s), 7.15-7.47 (7H, m), 7.09 (1H, t), 4.85 (1H, d), 4.12-4.20 (1H, m), 4.08 (1H, d), 3.77 (1H, t), 3.20 (1H, d), 2.95-3.10 (3H, m). LCMS:  $m/z$  338/340  $[M+H]^+$  @ Rt 3.9 min

**EXAMPLE 16**

10 (2R)-2-[(R)-(2-chloro-6-methylphenyl)thio](phenyl)methyl]morpholine hydrochloride


i)



15 To a solution of (2R)-4-benzyl-2 [(S)-bromo(phenyl)methyl]morpholine (200 mg, 0.6 mmol) and 2-chloro-6-methyl thiophenol (0.167ml, 6eq) in anhydrous DMF (5 ml) at room temperature under nitrogen was added potassium carbonate (100 mg, 0.7mmol, 1.2eq). The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was diluted with methanol and poured directly onto a SCX-2 column for  
20 purification to give (2R)-2-[(R)-(2-chloro-6-methylphenyl)thio](phenyl)methyl]-4-(phenyl)methyl]morpholine before taking directly onto the next step.

ii) (2R)-2-[(R)-(2-chloro-6 methylphenyl)thio](phenyl)methyl]morpholine hydrochloride

-61-




To a suspension of polymer supported Hunig's base (182mg, 3eq) and (2R)-2-[(R)-(2-chloro-6-methylphenyl)thio](phenyl)methyl-4-(phenyl)methylmorpholine (254mg, 0.6mmol) in dry DCM (5 ml) was added  $\alpha$ -chloroethyl chloroformate (0.187ml, 1.7mmol, 3 eq) at room temperature and under nitrogen. The mixture was allowed to stir at room temperature overnight. The reaction mixture was taken up in methanol (5 ml) and stirred at room temperature overnight. The reaction mixture was then treated with SCX-2 (10 g). After elution with methanol followed by elution with 7 N  $\text{NH}_3$ /methanol (2R)-2-[(R)-(2-chloro-6-methylphenyl)thio](phenyl)methylmorpholine was obtained as an oil (163 mg, 82% yield); MW 333;  $\text{C}_{18}\text{H}_{20}\text{ClNOS}$ ;  $^1\text{H}$  NMR (DMSO): 8.80 (1H, br s), 7.30 (1H, m), 7.20 (7H, m), 4.40 (1H, d, 8.2 Hz), 4.20 (1H, m), 4.00 (1H, m), 3.80 (1H, m), 3.15 (1H, m), 2.90 (2H, m), 2.20 (3H, s) 1.20 (1H, m); LCMS (10 minutes method):  $m/z$  334 $[\text{M}+\text{H}]^+$  @  $R_T$  5.1 min; HPLC purity = 100% (UV<sub>215nm</sub>) / 100% (ELS). The free base was converted into the title product HCl salt.

15

**EXAMPLE 17:**


**(2R)-2-((R)-[4-fluorophenyl][2-methoxyphenyl]thio)methylmorpholine hydrochloride**



i)


-62-

## Diastereomer 1



Following the procedure described in example 5(i), 4-benzylmorpholin-3-one (4.06g) was converted to 2-(R)-2-[(S)-(4-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and 2-(S)-2-[(R)-(4-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one. Crystallised from hexane-ethyl acetate to give a colourless solid (2.04g).


ii)



2-(R)-2-[(S)-(4-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one and 2-(S)-2-[(R)-(4-fluorophenyl)(hydroxy)methyl]-4-benzylmorpholin-3-one (2.0g) was converted to (R)-[4-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[4-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol following procedure described in example 2(ii) to give a colourless oil (1.88g).

15


iii)



-63-

To a stirred solution of (R)-[4-fluorophenyl][(2R)-4-benzylmorpholin-2-yl]methanol and (S)-[4-fluorophenyl][(2S)-4-benzylmorpholin-2-yl]methanol (1.64g, 5.54mmol) and triphenylphosphine (2.32g, 8.86mmol) in anhydrous chloroform (40ml) was added solid carbon tetrabromide (2.76g, 8.31mmol) in one lot. The solution was heated at reflux under nitrogen for 3h. Cooled and washed reaction mixture with brine, dried, filtered and evaporated to a red oil. The oil was purified by chromatography on silica eluting with hexane:ethyl acetate 41:9 to give 2(R)-2-[(S)-bromo(4-fluorophenyl)methyl]-4-benzylmorpholine and 2(S)-2-[(R)-bromo(4-fluorophenyl)methyl]-4-benzylmorpholine as a colourless oil (0.49g)

iv)




To a stirred suspension of 2(R)-2-[(S)-bromo(4-fluorophenyl)methyl]-4-benzylmorpholine and 2(S)-2-[(R)-bromo(4-fluorophenyl)methyl]-4-benzylmorpholine (0.6g, 1.65mmol) and cesium carbonate (0.59g, 1.81mmol) in dry DMF (5ml) was added 2-methoxybenzenethiol (0.25g, 1.81mmol). The suspension was heated at 90°C under nitrogen for 3h. The cooled reaction mixture was diluted with water and extracted with diethyl ether. The extracts were washed with water and brine, dried, filtered and evaporated to an oil. The crude oil was purified by chromatography on silica eluting with hexane:ethyl acetate 4:1 then 3:2 to give (2R)-2-((R)-(4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine and (2S)-2-((S)-(4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine a colourless oil (0.22g)



-64-

v)



Reaction of the mixture of (2*R*)-2-((*R*)-(4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine and (2*S*)-2-((*S*)-(4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine (430 mg, 1.02 mmol) following procedure described in EXAMPLE 1(iv) gave a colourless oil (340 mg, 90% yield) from which first eluting enantiomer (2*R*)-2-((*R*)-(4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine was obtained after chiral chromatography on a Chiralcel-OD column eluant heptane/isopropanol/dimethylethylamine (50/50/0.2): *R*<sub>t</sub> 10.58 min. This was converted into its hydrochloride salt. <sup>1</sup>H NMR (CD<sub>3</sub>OD): 7.01-7.20 (4H, m), 6.70-6.80 (3H, m), 6.60 (1H, t), 4.37 (1H, d), 3.82-3.90 (1H, m), 3.70-3.79 (4H, m), 3.49-3.60 (1H, m), 2.70-2.78 (2H, m), 2.60-2.70 (2H, m).

The pharmacological profile of the present compounds may be demonstrated as follows. All of the exemplified compounds above have been found to exhibit a *K<sub>i</sub>* value less than 100nM at the serotonin transporter and a *K<sub>i</sub>* value less than 100nM at the norepinephrine transporter as determined using the scintillation proximity assays described below. Furthermore, all of the exemplified compounds above have been found to selectively inhibit the serotonin and norepinephrine transporters relative to the dopamine transporter by a factor of at least five using the scintillation proximity assays as described below.

#### Generation of stable cell-lines expressing the human dopamine, norepinephrine and serotonin transporters

Standard molecular cloning techniques were used to generate stable cell-lines expressing the human dopamine, norepinephrine and serotonin transporters. The polymerase chain reaction (PCR) was used in order to isolate and amplify each of the

-65-

three full-length cDNAs from an appropriate cDNA library. Primers for PCR were designed using the following published sequence data:

- Human dopamine transporter: GenBank M95167. Reference: Vandenberg DJ, Persico AM and Uhl GR. *A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs*. Molecular Brain Research (1992) volume 15, pages 161-166.

- Human norepinephrine transporter: GenBank M65105. Reference: Pacholczyk T, Blakely, RD and Amara SG. *Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter*. Nature (1991) volume 350, pages 350-354.

- Human serotonin transporter: GenBank L05568. Reference: Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V and Blakely RD. *Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization*. Proceedings of the National Academy of Sciences of the USA (1993) volume 90, pages 2542-2546.

- The PCR products were cloned into a mammalian expression vector (eg pcDNA3.1 (Invitrogen)) using standard ligation techniques. The constructs were then used to stably transfect HEK293 cells using a commercially available lipofection reagent (Lipofectamine<sup>TM</sup> – Invitrogen) following the manufacture's protocol.

- Scintillation proximity assays for determining the affinity of test ligands at the norepinephrine and serotonin transporters.

- The compounds of the present invention are norepinephrine and serotonin reuptake inhibitors, and possess excellent activity in, for example, a scintillation proximity assay (e.g. J. Gobel, D.L. Saussy and A. Goetz, J. Pharmacol. Toxicol. (1999), 42, 237-244). Thus <sup>3</sup>H-nisoxetine binding to norepinephrine re-uptake sites in a cell line transfected with DNA encoding human norepinephrine transporter binding protein and similarly <sup>3</sup>H-citalopram binding to serotonin re-uptake sites in a cell line transfected with DNA encoding human serotonin transporter binding protein have been used to determine the affinity of ligands at the norepinephrine and serotonin transporters respectively.

30

#### Norepinephrine Binding Assay

##### Membrane Preparation:

-66-

Cell pastes from large scale production of HEK-293 cells expressing cloned human norepinephrine transporters were homogenized in 4 volumes 50mM Tris-HCl containing 300mM NaCl and 5mM KCl, pH 7.4. The homogenate was centrifuged twice (40,000g, 10min, 4°C) with pellet re-suspension in 4 volumes of Tris-HCl buffer containing the above reagents after the first spin and 8 volumes after the second spin. The suspended homogenate was centrifuged (100g, 10min, 4°C) and the supernatant kept and re-centrifuged (40,000g, 20min, 4°C). The pellet was resuspended in Tris-HCl buffer containing the above reagents along with 10%w/v sucrose and 0.1mM phenylmethylsulfonyl fluoride (PMSF). The membrane preparation was stored in aliquots (1ml) at -80°C until required. The protein concentration of the membrane preparation was determined using a bicinchoninic acid (BCA) protein assay reagent kit (available from Pierce).

#### [<sup>3</sup>H]-Nisoxetine Binding Assay:

- Each well of a 96 well microtitre plate was set up to contain the following:
- |      |   |
|------|---|
| 50μl | 2nM [N-methyl- <sup>3</sup> H]-Nisoxetine hydrochloride (70-87Ci/mmol, from NEN Life Science Products)        |
| 75μl | Assay buffer (50mM Tris-HCl pH 7.4 containing 300mM NaCl and 5mM KCl)   |
| 25μl | Test compound, assay buffer (total binding) or 10μM Desipramine HCl (non-specific binding)                    |
| 50μl | Wheatgerm agglutinin coated poly (vinyltoluene) (WGA PVT) SPA Beads (Amersham Biosciences RPNQ0001) (10mg/ml) |
| 50μl | Membrane (0.2mg protein per ml)   |

The microtitre plates were incubated at room temperature for 10 hours prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide K<sub>i</sub> values for each of the test compounds.

#### Serotonin Binding Assay

- The ability of a test compound to compete with [<sup>3</sup>H]-citalopram for its binding sites on cloned human serotonin transporter containing membranes has been used as a

-67-

measure of test compound ability to block serotonin uptake via its specific transporter (Ramamoorthy, S., Giovanetti, E., Qian, Y., Blakely, R., (1998) J. Biol. Chem. 273, 2458).

#### 5 Membrane Preparation:

Membrane preparation is essentially similar to that for the norepinephrine transporter containing membranes as described above. The membrane preparation was stored in aliquots (1ml) at -70°C until required. The protein concentration of the membrane preparation was determined using a BCA protein assay reagent kit.

10

#### [<sup>3</sup>H]-Citalopram Binding Assay:

Each well of a 96 well microtitre plate was set up to contain the following:

- 50µl 2nM [<sup>3</sup>H]-Citalopram (60-86Ci/mmol, Amersham Biosciences)
- 75µl Assay buffer (50mM Tris-HCl pH 7.4 containing 150mM NaCl and 5mM KCl)
- 15 25µl Diluted compound, assay buffer (total binding) or 100µM Fluoxetine (non-specific binding)
- 50µl WGA PVT SPA Beads (40mg/ml)
- 50µl Membrane preparation (0.4mg protein per ml)

The microtitre plates were incubated at room temperature for 10 hours prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide K<sub>i</sub> (nM) values for each of the unknown compounds.

20

#### Dopamine Binding Assay

25

The ability of a test compound to compete with [<sup>3</sup>H]-WIN35,428 for its binding sites on human cell membranes containing cloned human dopamine transporter has been used as a measure of the ability of such test compounds to block dopamine uptake via its specific transporter (Ramamoorthy et al 1998 *supra*).

#### 30 Membrane Preparation:

-68-

Is essentially the same as for membranes containing cloned human serotonin transporter as described above.

**[<sup>3</sup>H]-WIN35,428 Binding Assay:**

- 5        Each well of a 96well microtitre plate was set up to contain the following:
- 50μl    4nM [<sup>3</sup>H]-WIN35,428 (84-87Ci/mmol, from NEN Life Science Products)
- 75μl    Assay buffer (50mM Tris-HCl pH 7.4 containing 150mM NaCl and 5mM KCl)
- 25μl    Diluted compound, assay buffer (total binding) or 100μM Nomifensine (non-specific binding)
- 10    50μl    WGA PVT SPA Beads (10mg/ml)
- 50μl    Membrane preparation (0.2mg protein per ml.)

The microtitre plates were incubated at room temperature for 120 minutes prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide Ki values

15    for each of the unknown compounds.

**Formalin Paw Assay**

The analgesic effect of compounds of the invention for the treatment of persistent nociceptive pain was demonstrated using the well-known "formalin test." The formalin

20    test is a model of persistent nociceptive activation induced by tissue injury which can lead to central sensitization. (Shibata, M., Ohkubo, T., Takahashi, H., and Inoki, R., "Modified formalin test: Characteristic biphasic pain response," *Pain* (1989) 38: 347-352; and Tjolsen, A., Berge, O.G., Hunskaar, S., Rosland, J.H., and Hole, K., "The formalin test: an evaluation of the method," *Pain* (1992) 51:5-17.) The effect of compounds of the

25    invention on formalin-induced paw-licking behavior in the rat was investigated as an index of persistent nociceptive activation. In this test, the injection of formalin under the skin on the dorsal lateral surface of the hind paw of rats causes an immediate and intense increase in the spontaneous activity of C fiber afferents. This activation evokes a distinctly quantifiable behavior indicative of pain, such as licking of the injected paw.

30    The behavioral response to formalin is biphasic, with an early phase that is short lived, followed by an extended tonic response or late phase of persistent nociceptive activation.

Mechanisms causing the late phase response, such as central sensitization of pain transmitting neurons, are currently believed to contribute to various types of persistent pains.

Male Sprague-Dawley rats (200-250g; Charles River, Portage, MI) were maintained at constant temperature and light (12h light/12h dark) for 4-7 days prior to the studies. Animals had free access to food and water at all times prior to the day of the experiment.

The formalin test was performed in custom made Plexiglas® boxes 25x25x20 cm (length x width x height) in size. A mirror placed at the back of the box allowed the unhindered observation of the formalin injected paw. Rats were acclimatized individually in the cubicles at least 1 hour prior to the experiment. All testing was conducted between 08:00 and 14:00 hr and the testing room temperature was maintained at 21-23 °C. Test compound was administered 30 or 60 minutes prior to the formalin injection. Formalin (50 µl of a 5% solution in saline) was injected subcutaneously into the dorsal lateral surface of the right hind paw with a 27 gauge needle. Observation started immediately after the formalin injection. Formalin-induced pain was quantified by recording in 5 minute intervals the number of formalin injected paw licking events and the number of seconds each licking event lasted. These recordings were made for 50 minutes after the formalin injection. Scoring in the formalin test was performed according to Coderre *et al.*, 1993b and Abbott *et al.*, 1995. (Coderre T.J., Fundytus M.E., McKenna J.E., Dalal S. and Melzack R. "The formalin test: a validation of the weighted-scores method of the behavioral pain rating," *Pain*(1993b) 54: 43-50; and Abbott F.V., Franklin K.B.J. and Westbrook R.F. "The formalin test: scoring properties of the first and second phases of the pain response in rats," *Pain* (1995) 60: 91-102.) The sum of time spent licking in seconds from time 0 to 5 minutes was considered the early phase while the late phase was taken as the sum of seconds spent licking from 15 to 40 minutes.

#### In Vitro Determination of the Interaction of compounds with CYP2D6 in Human Hepatic Microsomes

Cytochrome P450 2D6 (CYP2D6) is a mammalian enzyme which is commonly associated with the metabolism of around 30% of pharmaceutical compounds. Moreover, this enzyme shows a genetic polymorphism with as a consequence a presence in the

-70-

population of poor and normal metabolizers. A low involvement of CYP2D6 in the metabolism of compounds (i.e. the compound being a poor substrate of CYP2D6) is desirable in order to reduce any variability from subject to subject in the pharmacokinetics of the compound. Also, compounds with a low inhibitor potential for CYP2D6 are desirable in order to avoid drug-drug interactions with co-administered drugs that are substrates of CYP2D6. Compounds may be tested both as substrates and as inhibitors of this enzyme by means of the following assays.

#### CYP2D6 substrate assay

##### 10 Principle:

This assay determines the extent of the CYP2D6 enzyme involvement in the total oxidative metabolism of a compound in microsomes. Preferred compounds of the present invention exhibit less than 75% total metabolism via the CYP2D6 pathway.

For this in vitro assay, the extent of oxidative metabolism in human liver microsomes (HLM) is determined after a 30 minute incubation in the absence and presence of Quinidine, a specific chemical inhibitor of CYP2D6. The difference in the extent of metabolism in absence and presence of the inhibitor indicates the involvement of CYP2D6 in the metabolism of the compound.

##### 20 Materials and Methods:

Human liver microsomes (mixture of 20 different donors, mixed gender) were acquired from Human Biologics (Scottsdale, AZ, USA). Quinidine and  $\beta$ -NADPH ( $\beta$ -Nicotinamide Adenine Dinucleotide Phosphate, reduced form, tetrasodium salt) were purchased from Sigma (St Louis, MO, USA). All the other reagents and solvents were of analytical grade. A stock solution of the new chemical entity (NCE) was prepared in a mixture of Acetonitrile/Water to reach a final concentration of acetonitrile in the incubation below 0.5%.

The microsomal incubation mixture (total volume 0.1 mL) contained the NCE (4  $\mu$ M),  $\beta$ -NADPH (1 mM), microsomal proteins (0.5 mg/mL), and Quinidine (0 or 2  $\mu$ M) in 100 mM sodium phosphate buffer pH 7.4. The mixture was incubated for 30 minutes at 37 °C in a shaking waterbath. The reaction was terminated by the addition of acetonitrile (75  $\mu$ L). The samples were vortexed and the denaturated proteins were removed by

-71-

centrifugation. The amount of NCE in the supernatant was analyzed by liquid chromatography /mass spectrometry (LC/MS) after addition of an internal standard. A sample was also taken at the start of the incubation (t=0), and analysed similarly.

Analysis of the NCE was performed by liquid chromatography /mass spectrometry. Ten  $\mu\text{L}$  of diluted samples (20 fold dilution in the mobile phase) were injected onto a Spherisorb CN Column, 5  $\mu\text{M}$  and 2.1 mm x 100 mm (Waters corp. Milford, MA, USA). The mobile phase consisting of a mixture of Solvent A/Solvent B, 30/70 (v/v) was pumped (Alliance 2795, Waters corp. Milford, MA, USA) through the column at a flow rate of 0.2 ml/minute. Solvent A and Solvent B were a mixture of ammonium formate  $5.10^{-3}$  M pH 4.5/ methanol in the proportions 95/5 (v/v) and 10/90 (v/v), for solvent A and solvent B, respectively. The NCE and the internal standard were quantified by monitoring their molecular ion using a mass spectrometer ZMD or ZQ (Waters-Micromass corp, Machester, UK) operated in a positive electrospray ionisation.

The extent of CYP2D6 involvement (% of CYP2D6 involvement) was calculated comparing the extent of metabolism in absence and in presence of quinidine in the incubation.

The extent of metabolism without inhibitor (%) was calculated as follows:

$$\frac{(\text{NCE response in samples without inhibitor})_{\text{time 0}} - (\text{NCE response in samples without inhibitor})_{\text{time 30}}}{(\text{NCE response in samples without inhibitor})_{\text{time 0}}} \times 100$$

The extent of metabolism with inhibitor (%) was calculated as follows:

$$\frac{(\text{NCE response in samples without inhibitor})_{\text{time 0}} - (\text{NCE response in samples with inhibitor})_{\text{time 30}}}{(\text{NCE response in samples without inhibitor})_{\text{time 0}}} \times 100$$

where the NCE response is the area of the NCE divided by the area of the internal standard in the LC/MS analysis chromatogram, time0 and time30 correspond to the 0 and 30 minutes incubation time.

The % of CYP2D6 involvement was calculated as follows:

$$\frac{(\% \text{ extent of metabolism without inhibitor}) - (\% \text{ extent of metabolism with inhibitor})}{\% \text{ extent of metabolism without inhibitor}} \times 100$$

#### CYP2D6 inhibitor assay



-72-

Principle:

The CYP2D6 inhibitor assay evaluates the potential for a compound to inhibit CYP2D6. This is performed by the measurement of the inhibition of the bufuralol 1'-hydroxylase activity by the compound compared to a control. The 1'-hydroxylation of bufuralol is a metabolic reaction specific to CYP2D6. Preferred compounds of the present invention exhibit an  $IC_{50}$  higher than 6  $\mu$ M for CYP2D6 activity, the  $IC_{50}$  being the concentration of the compound that gives 50 % of inhibition of the CYP2D6 activity.

Material and methods:

Human liver microsomes (mixture of 20 different donors, mixed gender) were acquired from Human Biologics (Scottsdale, AZ).  $\beta$ -NADPH was purchased from Sigma (St Louis, MO). Bufuralol was purchased from Ultrafine (Manchester, UK). All the other reagents and solvents were of analytical grade.

Microsomal incubation mixture (total volume 0.1 mL) contained bufuralol 10  $\mu$ M,  $\beta$ -NADPH (2 mM), microsomal proteins (0.5 mg/mL), and the new chemical entity (NCE) (0, 5, and 25  $\mu$ M) in 100 mM sodium phosphate buffer pH 7.4. The mixture was incubated in a shaking waterbath at 37 °C for 5 minutes. The reaction was terminated by the addition of methanol (75  $\mu$ L). The samples were vortexed and the denatured proteins were removed by centrifugation. The supernatant was analyzed by liquid chromatography connected to a fluorescence detector. The formation of the 1'-hydroxybufuralol was monitored in control samples (0  $\mu$ M NCE) and in the samples incubated in presence of the NCE. The stock solution of NCE was prepared in a mixture of Acetonitrile/Water to reach a final concentration of acetonitrile in the incubation below 1.0%.

The determination of 1'-hydroxybufuralol in the samples was performed by liquid chromatography with fluorimetric detection as described below. Twenty five  $\mu$ L samples were injected onto a Chromolith Performance RP-18e column (100 mm x 4.6 mm) (Merck KGAA, Darmstadt, Germany). The mobile phase, consisting of a mixture of solvent A and solvent B whose the proportions changed according the following linear gradient, was pumped through the column at a flow rate of 1 ml/min:

-73-

Time (minutes)	Solvent A (%)	Solvent B (%)
0	65	35
2.0	65	35
2.5	0	100
5.5	0	100
6.0	65	35

Solvent A and Solvent B consisted of a mixture of 0.02 M potassium dihydrogenophosphate buffer pH3/ methanol in the proportion 90/10 (v/v) for solvent A and 10/90 (v/v) for solvent B. The run time was 7.5 minutes. Formation of 1'-hydroxybufuralol was monitored by fluorimetric detection with extinction at  $\lambda$  252 nm and emission at  $\lambda$  302 nm.

The  $IC_{50}$  of the NCE for CYP2D6 was calculated by the measurement of the percent of inhibition of the formation of the 1'-hydroxybufuralol in presence of the NCE compared to control samples (no NCE) at a known concentration of the NCE.

The percent of inhibition of the formation of the 1'-hydroxybufuralol is calculated as follows:

$$\frac{(1'\text{-hydroxybufuralol formed without inhibitor}) - (1'\text{-hydroxybufuralol formed with inhibitor})}{(1'\text{-hydroxybufuralol area formed without inhibitor})} \times 100$$

The  $IC_{50}$  is calculated from the percent inhibition of the formation of the 1'-hydroxybufuralol as follows (assuming competitive inhibition):

$$\frac{NCE \text{ Concentration} \times (100 - \text{Percent of inhibition})}{\text{Percent of inhibition}}$$

The  $IC_{50}$  estimation is assumed valid if inhibition is between 20% and 80% (Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. 1999. Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29(1): 53-75).

-74-

**X-RAY CRYSTALLOGRAPHIC DATA**

Table 1. Crystal data and structure refinement for 2003xf.

5	Identification code	2003xf
	Empirical formula	C <sub>18</sub> H <sub>19</sub> Cl F <sub>3</sub> N O S
	Formula weight	389.85
	Temperature	107(2) K
	Wavelength	0.71073 Å
10	Crystal system, space group	Monoclinic, P2(1)
	Unit cell dimensions	a = 9.984(2) Å      alpha = 90 deg. b = 5.6484(13) Å    beta = 100.867(4) deg. c = 15.931(4) Å      gamma = 90 deg.
	Volume	882.4(4) Å <sup>3</sup>
15	Z, Calculated density	2, 1.467 Mg/m <sup>3</sup>
	Absorption coefficient	0.371 mm <sup>-1</sup>
	F(000)	404
	Crystal size	.06 x .08 x .18 mm
	Theta range for data collection	1.30 to 28.20 deg.
20	Limiting indices	11 ≤ h ≤ 13, -7 ≤ k ≤ 7, -20 ≤ l ≤ 19
	Reflections collected / unique	5986 / 3378 [R(int) = 0.0661]
	Completeness to theta = 28.20	92.9 %
	Absorption correction	None
	Refinement method	Full-matrix least-squares on F <sup>2</sup>
25	Data / restraints / parameters	3378 / 1 / 234
	Goodness-of-fit on F <sup>2</sup>	0.846
	Final R indices [I > 2sigma(I)]	R1 = 0.0488, wR2 = 0.0908
	R indices (all data)	R1 = 0.1227, wR2 = 0.1101
	Absolute structure parameter	0.11(10)
30	Largest diff. peak and hole	0.548 and -0.444 e.Å <sup>-3</sup>

-75-

X-RAY CRYSTALLOGRAPHIC DATATable 2. Atomic coordinates ( $\times 10^4$ ) and equivalent isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for 2003xf.

5

U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.

	x	y	z	U(eq)
10	S(8)	8641(1)	5291(2)	2641(1) 35(1)
	O(1)	10279(3)	2645(5)	4200(2) 24(1)
	C(7)	9992(5)	3088(8)	2678(3) 25(1)
	F(3)	5136(4)	4842(7)	443(2) 65(1)
	N(4)	13055(4)	1352(9)	4386(3) 21(1)
15	C(5)	12147(4)	1431(8)	3536(3) 22(1)
	F(2)	7264(4)	4253(5)	644(2) 51(1)
	C(20)	10490(5)	1794(8)	1263(3) 31(1)
	F(1)	6497(4)	7227(5)	1228(2) 48(1)
	C(15)	10669(5)	3416(8)	1925(3) 24(1)
20	C(6)	11008(5)	3187(8)	3525(3) 24(1)
	C(16)	11472(5)	5394(10)	1846(3) 32(1)
	C(10)	6184(5)	3389(9)	1805(3) 26(1)
	C(13)	5978(5)	382(11)	3117(4) 40(1)
	C(9)	7190(5)	3438(9)	2506(3) 30(1)
25	C(3)	12283(5)	976(8)	5085(3) 27(1)
	C(12)	4992(5)	364(10)	2423(3) 31(1)
	C(2)	11168(5)	2787(9)	5010(3) 28(1)
	C(21)	6253(6)	4934(11)	1033(4) 41(2)
	C(18)	11846(5)	4080(10)	494(3) 33(1)
30	C(17)	12048(5)	5721(9)	1131(4) 36(1)
	C(19)	11078(5)	2138(9)	552(4) 35(1)
	C(11)	5062(5)	1943(9)	1738(4) 42(2)
	C(14)	7065(6)	1852(10)	3160(4) 43(2)
	Cl(1)	4131(1)	6360(2)	4214(1) 30(1)

35

X-RAY CRYSTALLOGRAPHIC DATA

Table 3. Bond lengths [Å] and angles [deg] for 2003xf.

5	S(8)-C(9)	1.767(5)
	S(8)-C(7)	1.828(5)
	O(1)-C(2)	1.424(5)
	O(1)-C(6)	1.440(5)
	C(7)-C(15)	1.495(6)
10	C(7)-C(6)	1.528(6)
	F(3)-C(21)	1.318(6)
	N(4)-C(5)	1.481(5)
	N(4)-C(3)	1.484(6)
	C(5)-C(6)	1.507(6)
15	F(2)-C(21)	1.337(6)
	C(20)-C(19)	1.385(7)
	C(20)-C(15)	1.383(6)
	F(1)-C(21)	1.343(6)
	C(15)-C(16)	1.395(6)
20	C(16)-C(17)	1.382(7)
	C(10)-C(9)	1.354(6)
	C(10)-C(11)	1.374(7)
	C(10)-C(21)	1.520(8)
	C(13)-C(12)	1.334(6)
25	C(13)-C(14)	1.358(7)
	C(9)-C(14)	1.397(7)
	C(3)-C(2)	1.500(6)
	C(12)-C(11)	1.421(7)
	C(18)-C(19)	1.351(7)
30	C(18)-C(17)	1.360(7)
	C(9)-S(8)-C(7)	100.6(2)
	C(2)-O(1)-C(6)	110.4(4)
	C(15)-C(7)-C(6)	112.3(4)
	C(15)-C(7)-S(8)	109.4(3)
35	C(6)-C(7)-S(8)	111.5(3)
	C(5)-N(4)-C(3)	112.0(4)
	N(4)-C(5)-C(6)	11.2(4)
	C(19)-C(20)-C(15)	121.2(5)

- 77 -

	C(20)-C(15)-C(16)	117.1(5)
	C(20)-C(15)-C(7)	121.1(5)
	C(16)-C(15)-C(7)	121.8(5)
	O(1)-C(6)-C(5)	109.7(4)
5	O(1)-C(6)-C(7)	107.9(4)
	C(5)-C(6)-C(7)	111.1(4)
	C(17)-C(16)-C(15)	121.2(5)
	C(9)-C(10)-C(11)	122.9(5)
	C(9)-C(10)-C(21)	121.0(5)
10	C(11)-C(10)-C(21)	116.0(5)
	C(12)-C(13)-C(14)	120.3(6)
	C(10)-C(9)-C(14)	116.4(5)
	C(10)-C(9)-S(8)	125.2(4)
	C(14)-C(9)-S(8)	118.4(4)
15	N(4)-C(3)-C(2)	109.0(4)
	C(13)-C(12)-C(11)	119.7(5)
	O(1)-C(2)-C(3)	111.1(4)
	F(3)-C(21)-F(1)	107.1(5)
	F(3)-C(21)-F(2)	105.6(5)
20	F(1)-C(21)-F(2)	105.4(5)
	F(3)-C(21)-C(10)	113.2(5)
	F(1)-C(21)-C(10)	113.6(5)
	F(2)-C(21)-C(10)	111.4(5)
	C(19)-C(18)-C(17)	120.6(5)
25	C(18)-C(17)-C(16)	119.8(5)
	C(18)-C(19)-C(20)	120.2(5)
	C(10)-C(11)-C(12)	118.1(5)
	C(13)-C(14)-C(9)	122.5(5)

---

30 Symmetry transformations used to generate equivalent atoms:

X-RAY CRYSTALLOGRAPHIC DATATable 4. Anisotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for 2003xf.

- 5 The anisotropic displacement factor exponent takes the form:  $-2 \pi^2 [h^2 a^{*2} U_{11} + \dots + 2 h$   
 $k a^* b^* U_{12}]$

		U11	U22	U33	U23	U13	U12
10	S(8)	24(1)	24(1)	53(1)	-1(1)	-1(1)	4(1)
	O(1)	24(2)	23(2)	24(2)	3(2)	0(2)	-2(2)
	C(7)	20(3)	23(2)	27(3)	-3(2)	-8(3)	0(2)
	F(3)	55(2)	88(3)	42(2)	15(2)	-16(2)	-13(2)
	N(4)	19(2)	14(2)	31(3)	3(2)	3(2)	-3(3)
15	C(5)	22(3)	16(2)	26(3)	-4(2)	2(2)	2(3)
	F(2)	69(3)	53(2)	39(2)	5(2)	29(2)	3(2)
	C(20)	29(3)	28(3)	31(3)	-12(3)	-5(3)	-1(2)
	F(1)	61(2)	35(2)	46(2)	5(2)	5(2)	5(2)
	C(15)	20(3)	22(3)	27(3)	2(3)	-3(2)	5(2)
20	C(6)	23(3)	17(2)	33(3)	-1(2)	11(3)	1(2)
	C(16)	40(3)	22(2)	31(3)	-3(3)	1(3)	-7(3)
	C(10)	20(3)	30(3)	27(3)	2(3)	8(3)	4(3)
	C(13)	33(3)	45(3)	42(4)	3(3)	7(3)	0(3)
	C(9)	20(3)	38(3)	31(4)	-8(3)	2(3)	7(3)
25	C(3)	22(3)	28(3)	32(3)	10(2)	5(2)	0(2)
	C(12)	22(3)	29(2)	41(4)	-1(3)	8(3)	-7(3)
	C(2)	28(3)	34(3)	22(3)	-2(3)	3(3)	4(2)
	C(21)	27(4)	50(4)	43(4)	-16(3)	-1(3)	10(3)
	C(18)	24(3)	44(3)	30(4)	-1(3)	3(3)	11(3)
30	C(17)	42(4)	26(3)	40(4)	0(3)	9(3)	-6(2)
	C(19)	33(3)	38(3)	33(4)	-9(3)	2(3)	6(3)
	C(11)	20(3)	49(4)	52(4)	-18(3)	-3(3)	8(3)
	C(14)	35(4)	72(5)	22(3)	16(3)	-1(3)	-4(3)
35	Cl(1)	24(1)	16(1)	46(1)	1(1)	-1(1)	-1(1)

-79-

X-RAY CRYSTALLOGRAPHIC DATATable 5. Hydrogen coordinates (  $\times 10^4$ ) and isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for 2003xf.

		x	y	z	U(eq)
5	H(7A)	9558	1486	2630	30
	H(5A)	11757	-162	3392	26
10	H(5B)	12685	1877	3099	26
	H(20A)	9954	420	1297	37
	H(6A)	11398	4819	3611	29
	H(16A)	11626	6536	2292	38
	H(13A)	5919	-637	3583	48
15	H(3A)	12902	1128	5645	33
	H(3B)	11886	-636	5043	33
	H(12A)	4246	-700	2387	37
	H(2A)	10639	2529	5468	34
	H(2B)	11575	4389	5085	34
20	H(18A)	12248	4302	5	40
	H(17A)	12584	7087	1084	43
	H(19A)	10941	1005	103	42
	H(11A)	4354	1998	1248	50
	H(14A)	7767	1799	3653	52
25	H(4B)	13680(60)	2600(100)	4430(30)	53(19)
	H(4A)	13580(50)	230(90)	4400(30)	29(17)



**X-RAY CRYSTALLOGRAPHIC DATA****Table 6. Torsion angles [deg] for 2003xf.**

5	C(9)-S(8)-C(7)-C(15)	115.5(4)
	C(9)-S(8)-C(7)-C(6)	-119.7(4)
	C(3)-N(4)-C(5)-C(6)	52.2(6)
	C(19)-C(20)-C(15)-C(16)	-0.4(7)
	C(19)-C(20)-C(15)-C(7)	177.8(4)
10	C(6)-C(7)-C(15)-C(20)	126.4(5)
	S(8)-C(7)-C(15)-C(20)	-109.2(4)
	C(6)-C(7)-C(15)-C(16)	-55.5(6)
	S(8)-C(7)-C(15)-C(16)	68.9(5)
	C(2)-O(1)-C(6)-C(5)	60.7(5)
15	C(2)-O(1)-C(6)-C(7)	-178.1(4)
	N(4)-C(5)-C(6)-O(1)	-55.1(5)
	N(4)-C(5)-C(6)-C(7)	-174.3(4)
	C(15)-C(7)-C(6)-O(1)	-175.0(4)
	S(8)-C(7)-C(6)-O(1)	61.9(4)
20	C(15)-C(7)-C(6)-C(5)	-54.7(5)
	S(8)-C(7)-C(6)-C(5)	-177.8(3)
	C(20)-C(15)-C(16)-C(17)	0.7(7)
	C(7)-C(15)-C(16)-C(17)	-177.4(5)
	C(11)-C(10)-C(9)-C(14)	2.6(8)
25	C(21)-C(10)-C(9)-C(14)	-176.4(5)
	C(11)-C(10)-C(9)-S(8)	-178.8(4)
	C(21)-C(10)-C(9)-S(8)	2.2(7)
	C(7)-S(8)-C(9)-C(10)	-114.6(5)
	C(7)-S(8)-C(9)-C(14)	64.0(5)
30	C(5)-N(4)-C(3)-C(2)	-52.6(6)
	C(14)-C(13)-C(12)-C(11)	-1.9(8)
	C(6)-O(1)-C(2)-C(3)	-63.3(5)
	N(4)-C(3)-C(2)-O(1)	58.2(5)
	C(9)-C(10)-C(21)-F(3)	-173.8(5)
35	C(11)-C(10)-C(21)-F(3)	7.1(7)
	C(9)-C(10)-C(21)-F(1)	-51.3(7)
	C(11)-C(10)-C(21)-F(1)	129.6(5)
	C(9)-C(10)-C(21)-F(2)	67.4(7)

-81-

	C(11)-C(10)-C(21)-F(2)	-111.6(5)
	C(19)-C(18)-C(17)-C(16)	0.5(8)
	C(15)-C(16)-C(17)-C(18)	-0.7(8)
	C(17)-C(18)-C(19)-C(20)	-0.2(8)
5	C(15)-C(20)-C(19)-C(18)	0.1(8)
	C(9)-C(10)-C(11)-C(12)	-2.7(8)
	C(21)-C(10)-C(11)-C(12)	176.3(5)
	C(13)-C(12)-C(11)-C(10)	2.3(8)
	C(12)-C(13)-C(14)-C(9)	1.9(8)
10	C(10)-C(9)-C(14)-C(13)	-2.1(8)
	S(8)-C(9)-C(14)-C(13)	179.2(4)


---

Symmetry transformations used to generate equivalent atoms

- 82 -

## CLAIMS

1. A compound of formula (I)



5

wherein

R is H;

Ar is an aromatic group selected from unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl),

- 10 halo, and phenyl optionally substituted with halo, C<sub>1</sub>-C<sub>4</sub> alkyl or O(C<sub>1</sub>-C<sub>4</sub> alkyl);

X is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), and halo;


R' is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

each R<sup>1</sup> is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

- 15 wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, represented by formula II:



20

-83-

in which R<sub>2</sub> and R<sub>3</sub> are each independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, and phenyl; and

R<sub>4</sub> is selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl) and halo;

wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or

5 more halo atoms;

or a pharmaceutically acceptable salt thereof.

3. A compound as claimed in claim 2, wherein R<sub>2</sub> is selected from C<sub>1</sub>-C<sub>2</sub> alkyl, O(C<sub>1</sub>-C<sub>2</sub> alkyl), S(C<sub>1</sub>-C<sub>2</sub> alkyl), Cl and F wherein each above-mentioned C<sub>1</sub>-C<sub>2</sub> alkyl  
10 group is optionally substituted with one or more halo atoms.

4. A compound as claimed in claim 2 or claim 3, wherein R<sub>3</sub> is selected from H, Me and Cl.

15 5. A compound as claimed in any one of the claims 2 to 4, wherein R<sub>4</sub> is selected from H, C<sub>1</sub>-C<sub>2</sub> alkyl, O(C<sub>1</sub>-C<sub>2</sub> alkyl), Cl and F wherein each above-mentioned C<sub>1</sub>-C<sub>2</sub> alkyl group is optionally substituted with one or more halo atoms.

20 6. A compound as claimed in any one of claims 1-5, for use as a pharmaceutical.

7. A compound as claimed in any one of claims 1-5, for use as a selective inhibitor of the reuptake of serotonin and norepinephrine.

25 8. The use of a compound as claimed in any one of claims 1-5, for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals.

9. The use of a compound as claimed in any one of claims 1-5, for the manufacture of a medicament for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals.

30

-84-

10. A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5.
- 5 11. A method for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5.
- 10 12. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain.
13. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is selected from depression, stress urinary incontinence and pain.
- 15 14. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is pain.
- 20 15. A composition comprising a compound as claimed in any one of claims 1-5 together with a pharmaceutically acceptable diluent, excipient or carrier.

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D265/30 A61K31/5375 A61P25/24

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 01973 A (MARSHALL ROBERT CLYDE ;UPJOHN CO (US); WONG ERIK H F (US); BIRGERS) 11 January 2001 (2001-01-11) cited in the application pages 4-6, formulae (I), (II), (III), (IV) page 18, line 20 -page 19, line 19	1-14
A	WO 00 39091 A (SEGELSTEIN BARBARA EILEEN ;LIRAS SPIROS (US); PFIZER PROD INC (US)) 6 July 2000 (2000-07-06) page 1, formula I page 8, line 7 - line 32	1-14

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

10 December 2003

Date of mailing of the international search report

23/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/23268

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 6-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23268

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
WO 0101973	A	11-01-2001	AU 5633700 A	22-01-2001			
			BR 0012136 A	11-06-2002			
			CA 2375908 A1	11-01-2001			
			CN 1379672 T	13-11-2002			
			CZ 20014625 A3	14-08-2002			
			EP 1196172 A2	17-04-2002			
			HU 0201623 A2	28-09-2002			
			JP 2003503450 T	28-01-2003			
			NO 20016406 A	19-02-2002			
			SK 19382001 A3	02-07-2002			
			WO 0101973 A2	11-01-2001			
			US 2002061910 A1	23-05-2002			
			US 2002086864 A1	04-07-2002			
			US 2002107249 A1	08-08-2002			
			US 2002128173 A1	12-09-2002			
			US 2003040464 A1	27-02-2003			
			US 6465458 B1	15-10-2002			
			ZA 200110325 A	14-03-2003			
			WO 0039091	A	06-07-2000	AU 760874 B2	22-05-2003
						AU 1290500 A	31-07-2000
BG 105731 A	28-02-2002						
BR 9916680 A	13-11-2001						
CA 2350589 A1	06-07-2000						
CN 1332727 T	23-01-2002						
CZ 20012388 A3	11-09-2002						
EE 200100347 A	16-12-2002						
EP 1140835 A1	10-10-2001						
HR 20010491 A1	31-08-2002						
HU 0105075 A2	29-04-2002						
WO 0039091 A1	06-07-2000						
JP 2002538083 T	12-11-2002						
NO 20013237 A	28-08-2001						
NZ 511791 A	29-08-2003						
PL 348668 A1	03-06-2002						
SK 9012001 A3	03-12-2002						
TR 200101978 T2	21-12-2001						
US 6503905 B1	07-01-2003						
US 6586431 B1	01-07-2003						
ZA 200104255 A	24-06-2002						